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Anaemia is a global health concern affecting billions of people worldwide. In 
developing countries the predominance of nutritional iron deficiency significantly 
contributes to the problem of anaemia and this is indicated in the high prevalence 
of iron deficiency anaemia in the general population. Despite being a major problem, 
treatment of iron deficiency anaemia is not costly and can be administered with 
relative ease. The d i a g n o s i s  of iron deficiency anaemia however, requires a 
multidisciplinary approach within the medical laboratory sections consequently 
resulting in the generation of a multitude of test results. The diagnostic approach to 
iron deficiency anaemia can be streamlined in an attempt to increase diagnostic 
sensitivity and to reduce uncertainties in interpreting laboratory generated data thus, 
the main aim of this study was to establish the usefulness of Hepcidin in the 
diagnosis and prognosis of iron deficiency anaemia. The other aim was to establish 
Hepcidin reference normal range values in Namibia for use in this study. 
 
In establishing the reference normal range, a total of forty healthy adult participants 
were randomly selected from eligible blood donors. Forty-five participants with iron 
deficiency anaemia were also randomly selected to characterise the quantitative 
behaviour of Hepcidin in iron deplete states. More participants with iron deficiency 
were recruited compared to the number for healthy participants in order to cater for 
sample attrition. After accounting for sample attrition, a total of forty participants with 
iron deficiency who were on treatment were tested. 
 
The introduction of Hepcidin testing in a routine diagnostic laboratory has potential 
in improving the diagnosis and prognosis of iron deficiency anaemia. In this study, 
serum Hepcidin reference normal range values for adults were established to be 
17.803-86.181ng/mL among blood donors in Namibia. Participants with features 
suggestive of iron deficiency anaemia had suppressed serum Hepcidin values when 
compared to the established reference normal range. The serum Hepcidin 
concentrations however increased to normal levels on following up iron deficient 
participants who had been on iron treatment. The dynamics of Hepcidin was 




usefulness of Hepcidin in assessing iron bioavailability in iron deficiency anaemia. 
Correlation analysis indicated moderate but better associations between 
haemoglobin and Hepcidin compared to haemoglobin and serum iron levels. 
Anaemia  had  a  better  effect  on  serum  Hepcidin  (r=0.112)  than  serum  iron 
(r=0.015) strengthening the case for using Hepcidin. Multiple regression analysis 
of the iron deficiency anaemia group before and after iron treatment showed 
statistically significant positive correlation between pre-treatment Hepcidin and 
serum iron (r= 0.456 p=0.003). Similarly, a moderate positive association between 
Δ Hepcidin and Δ serum iron (r= 0.319) was shown confirming the consistent 
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Anaemia is characterized by a reduction in haemoglobin levels with or without 
accompanying reduction in red cell counts.  The reduction could either be due to 
depressed rate of production or accelerated rate of destruction of the red blood cells. 
There are different types of anaemia and these are usually classified according to 
the aetiology of the anaemia. Iron deficiency can cause iron deficiency anaemia 
(IDA) because iron is required for the production of haeme which is the main 
component of haemoglobin. According to Hoffbrand and Moss (2011), Iron deficiency 
anaemia (IDA) is a haematological disorder characterised by a reduced level of 
haemoglobin which is attributed to inadequate iron bioavailability. In IDA, anaemia 
is due to depressed erythropoietic activity secondary to inadequate iron 
bioavailability. In the absence of sufficient amounts of iron, fewer red cells are 
produced which consequently result in reduced haemoglobin levels. Inadequate iron 
bioavailability can also cause production of morphologically distinct red cells which 
are microcytic, hypochromic and sometimes pencil shaped. These morphological 
features are a result of the significant reduction in haemoglobin content in the cells 
so produced.  
 
Globally more than 2.2 billion individuals were affected  with  anaemia as  of  2010 
(Kassebaum  et al.,2014). This accounts for more than 30% of the entire population 
worldwide of which iron deficiency anaemia was the most common cause 
(Kassebaum et al., 2014).   In our published work on donor deferrals, anaemia was 
found to be the main reason with almost 50% of deferred donors attributed to low 
haemoglobin (Gonzo et al., 2016). This goes on to show the magnitude of the anaemia 
problem even in presumably healthy populations such as blood donors. 
 
Towards the beginning of the twenty first century a report by UN and WHO indicated 
that in the adolescence populace there were about 2.5 cases of iron deficiency 
anaemia for every case of anaemia due to other causes (UNICEF/UNU/WHO 1998). 
According to WHO (2001) 50% of anaemia cases are due to nutritional  iron  
deficiency.   
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More recent WHO prevalence studies also concur that more than 40% of anaemia in 
children is attributable to iron deficiency (WHO 2015). It also confirms that about 50% 
of anaemia in women could be eliminated by iron supplementation (WHO 2015). These 
figures suggest that anaemia is a health concern. Anaemia, regardless of aetiology, 
can negatively affect productivity and quality of life of the affected individuals due to 
reduced tissue oxygenation. Reduced tissue oxygenation occurs as a result of 
inadequate haemoglobin which consequently results in reduced cellular oxidative 
capacity. Iron deficiency anaemia in particular, results in decreased physical 
work capacity, athletic performances and cognitive impairment (Hlatswayo et 
al 2016). 
 
Global prevalence data presented by Miller (2013) show that 64.6% of children in Africa  
are affected by anaemia. Iron deficiency anaemia (IDA), one of the anaemias is even 
more relevant in African developing countries and Namibia is not an exception. The 
WHO prevalence data on anaemia shows that anaemia due to nutritional deficiencies, 
in particular iron deficiency anaemia (IDA), present a considerable burden on health in 
developing countries (WHO 2011). 
 
Given the predominance of IDA in the world-wide prevalence data (WHO 2015), it is 
therefore important to direct research efforts to improve the diagnosis and 
management of this ailment. The diagnosis of medical conditions has always required 
specialised skill and professional judgement, and this applies to haematological 
disorders such as iron deficiency anaemia as well.  Research aimed at improving 
diagnostic sensitivity of iron deficiency anaemia is well placed and this investigation 
has been directed at exactly that. Increased diagnostic sensitivity would result in earlier 
detection of the disease in question, in this instance IDA. Once diagnosed earlier, 
treatment can be initiated much sooner as well. For IDA the treatment is simple and 
has a high success rate given that IDA is a nutritional deficiency disorder. 
 
The  diagnosis  of  IDA  relies  on  confirming  the presence of anaemia by determining 
the level of haemoglobin and detecting the presence of inadequate iron bioavailability 
(Thomas et al., 2013). Inadequate iron bioavailability refers to a state whereby there is 
not enough iron for normal physiological functions such as erythropoiesis. 
When there are insufficient iron supplies for erythropoietic activity the body invokes 
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compensatory mechanisms. These mechanisms would result in altered red blood cell 
shape and haemoglobin composition and in due course would result in anaemia. 
Inadequate iron bioavailability can be  detected using a variety of  approaches 
which include presence of distinctive red cell morphological characteristics indicative 
of iron underutilization and the presence of abnormal red cell indices obtainable from 
a full blood count such as mean corpuscular volume (MCV), mean corpuscular  
haemoglobin  (MCH)  and  mean  corpuscular  haemoglobin concentration  (MCHC).  
Inadequate  iron  bioavailability  can  also  be  detected through  biochemical  analysis  
of  blood  samples  to  confirm  the  presence  of abnormal iron studies results. Iron 
studies encompass serum ferritin, serum iron, total iron binding capacity and transferrin 
levels. A more invasive approach would be to collect a bone marrow sample and 
look for the presence of stainable iron deposits. This is done by staining a bone 
marrow aspirate with a pearls Prussian blue stain. A bone marrow biopsy is not 
usually required in this instance unless there is a failed aspirate or bone marrow 
fibrosis is suspected. 
 
Current UK guidelines on diagnosis of iron deficiency anaemia suggest the use of Full 
blood count results and serum ferritin levels (Thomas et al., 2013). Full blood count 
generates a battery of parameters which have to be interpreted in conjunction with 
another set of results for iron studies, a situation which complicates  the  decision  
making  process.    In  Namibia,   the  Namibia  standard treatment guidelines (MoHSS 
2011) informs the approach used to diagnose iron deficiency anaemia.  The Namibian 
guidelines rely on the findings of a low MCV, low  MCHC  together  with  a  microcytic  
hypochromic  blood  picture  in  order  to suspect iron deficiency anaemia. 
 
The current approaches do not make use of Hepcidin as a routine diagnostic tool for 
iron deficiency anaemia but Girelli et al., (2016) and other authors have highlighted its 
potential. Pasricha et al., (2013) has even advocated for Hepcidin point of care testing 
(POCT) as a research priority area in looking for ways to manage post malarial iron 
deficiency anaemia. According to Kroot et al., (2011) the measurement of Hepcidin 
is still a promising diagnostic tool, especially for the diagnosis and management of 
medical conditions in which iron metabolism is affected  such  as  iron  deficiency  
anaemia.  The  role  of  Hepcidin  in  directly regulating iron makes it a relevant marker 
of iron bioavailability. Hepcidin is sensitive to the dynamics of iron utilisation and could 
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potentially be used as a routine laboratory test to help in the diagnosis and 
management of patients with iron deficiency anaemia. A reduction in iron bioavailability 
results in reduced Hepcidin levels due to its suppressed expression. These features 
have resulted in the current UK guidelines (Thomas et al., 2013) alluding to the horizon 
of Hepcidin as potential marker in iron deficiency anaemia. 
 
1.1. Research aims 
 
The aims of this study a re  to investigate how hepcidin 25 (referred to as Hepcidin 
in this study) can be introduced into the mainstream routine diagnosis laboratory. The 
study intended to investigate how Hepcidin can be used as a more sensitive  routine  
diagnostic  test  for  patients  presenting  with  iron  deficiency anaemia in Namibia, 
a country where the prevalence of anaemia in general is around 40% (de Benoist et 
al., 2008) This research project intended to achieve this by establishing quantitative 
differences of hepcidin 25 (Hepcidin) molecules in participants with features suggestive 
of iron deficiency anaemia. The study capitalises on the established relationship 
between iron and Hepcidin and thus looked at iron deficiency anaemia in Namibia 
using participants with features suggestive   of   iron   deficiency   anaemia.   These   
features   include   reduced haemoglobin levels which correct when iron is introduced.  
Correction of anaemia post iron treatment being regarded as a confirmation for the 
presence of iron deficiency anaemia at initial presentation. In an attempt to come up 
with baseline Hepcidin values, the study worked on establishing Hepcidin reference 
normal ranges for the Namibian population as a starting point before any work on IDA 
was done. 
 
1.2. Specific objectives 
 
The specific objectives for this study were: 
 
• To  establish  the  reference  normal  range  for  Hepcidin  in  a  healthy  adult 
population in Namibia where healthy adult is defined as: participants between 
16 years and 65 years; haemoglobin >125g/L and eligible blood donors. The 
NaMBTS blood donation criteria was useful in  defining “normal healthy adult” 
• To assess the values of Hepcidin in iron deficiency anaemia in Namibia by 




• To characterise the quantitative behaviour of Hepcidin in participants receiving iron 
treatment. The quantitative behaviours of Hepcidin were characterised by 
assessing its correlations and independent associations with serum iron and full 
blood count parameters such as red cell indices and haemoglobin levels. 
 
1.3. Overview of experimental methods 
 
The study used an ELISA based Hepcidin assay to quantitate hepcidin 25 levels in 
three groups of participants namely reference normal range (RNR), pre- i r o n  
treatment iron deficiency anaemia group (Pre-Iron) and post iron treatment iron 
deficiency anaemia group (Post Iron). Full blood count and serum iron analysis was 
also performed on the same three study groups i.e. RNR, Pre-Iron and Post Iron. The 
full blood count analysis was carried out using ABX Pentra XL80 analyser. Serum 
iron assays were manually set up using the FerroZine iron kit manufactured by Chrono 
lab systems, SPAIN. 
 
Research on the first group has been aimed at establishing reference normal ranges 
while work on the second and third groups was devoted to characterizing the 
behaviour of Hepcidin in iron deficiency anaemia.  The three groups were: 1) healthy 
adults, 2) individuals with features suggestive of iron deficiency anaemia pre-iron 
treatment and 3) individuals with features suggestive of iron deficiency anaemia post 
iron treatment.  Correlation studies of current tests and Hepcidin assays were 
performed on participants from the groups being studied. In this study, collection of 
dual point data sets from patients on iron therapy was carried out by measuring serum 
iron, Hepcidin and full blood count parameters on IDA patients before and after 
treatment with iron. The data obtained was used to assess the potential usefulness of 
Hepcidin as a more sensitive biomarker in such clinical situations. 
 
1.4. Benefits of a successful outcome of research  
 
This research work looked at the usefulness of Hepcidin from a diagnostic point of 
view. In their review, Kroot et al., (2011) alluded to the fact that Hepcidin 
measurements may be useful in anticipating the fate of iron therapy in associated 
diseases such as iron deficiency anaemia. This research  therefore  worked  towards  
making  more  information  available  for clinicians by giving them further insight into 
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what happens to iron regulation by Hepcidin in patients who have iron deficiency 
anaemia. 
 
Establishment of the usefulness of Hepcidin assays if proved useful in clinical settings 
as described above may reduce the lead time to decision making and may also shorten 
patients’ hospital stay. The benefits of Hepcidin testing will go beyond reducing lead-
time to decision making due to its possible increased diagnostic sensitivity. It can also 
be used to manage IDA patients requiring simple routine surgical procedures by 
informing the surgical teams of the likely outcome of blood loss in terms of subsequent 
erythropoietic activity. Hepcidin levels above the lower limit of normal indicate 
supposedly adequate iron bioavailability and consequently competent  erythropoietic  
compensation.  On  the  other  hand  reduced  Hepcidin levels  signal  its  suppression  
as  a  result  of  iron  bioavailability.  The  extent  of reduced Hepcidin levels and its 
relationship with levels of erythropoietic activity was part of this research whose 
































Anaemia is the most common red cell disorder and it occurs when the concentration of 
haemoglobin (Hb) falls below normal levels for a person’s age and gender (Hoffbrand 
and Moss 2011 2010). The World Health Organization (WHO) defines anaemia as a 
decrease in the concentration of Hb and sets the haemoglobin thresholds at <130 g/L 
and < 110 g/L for adult males and non-pregnant females respectively (WHO 2011). 
The threshold as to what constitutes a reduced Hb varies according to gender, age and 
geographical location. In view of this, the World Health Organization also defines 
anaemia as Hb concentration below 110 g/L in pregnant women, 110g/L in children 
under five and 115g/L in older children (WHO 2011). The thresholds for defining 
anaemia in Namibia are different to those quoted by the WHO because of the variations 
in geographical locations.  In Namibia anaemia is defined o n  t h e  b a s i s  o f  
normal ranges as defined by the South Africa Institute of Medical Research (SAIMR) 
reference ranges for Haematology in the Namibia S tan da rd  Treatment Guidelines 
(Ministry of Health and Social Services 2011). It is defined as a haemoglobin value 
less than 143 g/L and 121g/L for adult males and non-pregnant females respectively 
(MoHSS 2011). 
 
A reduced haemoglobin (Hb) level is the hall mark of anaemia. In addition, other 
haematological values relevant to anaemia include Red Blood Cell Count (RBC), Red 
cell Distribution Width (RDW), haematocrit (HCT) as well as other red cell indices 
such as Mean Corpuscular volume (MCV), Mean Corpuscular Haemoglobin (MCH) 
and Mean Corpuscular Haemoglobin Concentration (MCHC). These additional 
parameters are useful in elucidating the different types of anaemias, in particular 
iron deficiency anaemia (IDA). Iron deficiency anaemia is a nutritional disorder 
affecting red cell production as a result of reduced iron bioavailability. Pasricha et 
al., (2013) state that treatment for IDA is simple, safe and effective. It is therefore 
prudent that accurate diagnosis is made to enable proper management of this 
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ailment. According to Pasricha et al., (2013), in 2004 WHO estimated that  IDA 
resulted in 273 000 deaths of which 31% of them were in Africa. Given the ease 
with which IDA can be managed, the importance of its diagnosis cannot be 
emphasized enough.  
 
Red cell indices such as MCV, MCH, MCHC and RDW give useful diagnostic 
information in IDA. A low haemoglobin value has a direct impact on the mean 
corpuscular haemoglobin (MCH) and the mean corpuscular haemoglobin 
concentration (MCHC) because these are indices derived from the Hb value and 
other red cell parameters. A mean corpuscular volume (MCV) is however a direct 
reflection of the average cell size of the red blood cells. This is reduced in iron 
deficiency anaemia as a physiological response to reduced iron bioavailability and 
consequently reduced haemoglobin (Hoffbrand and Moss 2011). During normal 
erythropoiesis, red blood cells are packaged with adequate amounts of haemoglobin. 
This however is not the case when there is insufficient iron. 
 
The red cell distribution width (RDW) gives an indication of how variable the cells are, 
and it is a good indicator of the extent of anisopoikilocytosis. This value is 
i n creased in iron deficiency anaemia because of the presence of microcytic red blood 
cells as well as other abnormally shaped cells such as pencil cells. Pencils cells are a 
common feature in iron deficiency anaemia (Provan 2007) to such an extent it has 
become a diagnostic morphological feature for this pathology. In their work, Sazawal 
et al., (2014) presented convincing results to motivate the use of only RDW and Hb, 
without the use of iron studies results, in the diagnosis of iron deficiency anaemia. 
The merit of this approach is however debatable given the fact that the RDW is only an 
indicator of red cell variability. 
 
2.2. Iron deficiency anaemia 
 
Iron deficiency anaemia is a condition with vague clinical presentation. It is a condition 
which is characterised by low iron bioavailability for normal physiological functions 
(Hlatswayo et al 2016). The reduced iron bioavailability results in restricted haemoglobin 
production leading to a detectable anaemia. Anaemia upregulates the production of 
erythropoietin, a hormone which stimulates red cell production. However, in iron 
deficiency, increased erythropoietin production does not correct the anaemia even 
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when red cell production is stimulated. This is due to the absence of iron, a major 
component for haemoglobin synthesis. 
 
Iron deficiency anaemia is a serious health problem that affects more than 2 billion 
people globally (WHO 2015). It is more prevalent in developing countries where 
nutritional deficiencies are rampant. The 2011 global prevalence data on anaemia 
indicated that more than 40% of all anaemia cases is attributed to iron deficiency 
(WHO2015). In Namibia a country among the Africa sub Saharan countries, the 
prevalence is even higher. WHO global data base on anaemia estimates the 
prevalence to be about 60% for Namibia (WHO 2008). Given the prevalence data on 
this disease it is important to pay attention on both its diagnosis and treatment. 
Furthermore, IDA has been estimated to cause about 800 000 deaths and a loss of 
more than 35 million disability adjusted life years worldwide (WHO/CDC 2005). These 
reports strengthen the case for efforts to focus on IDA especially from  diagnosis, 
treatment and prevention points of view.  
 
Iron is required on a daily basis to compensate for loses from the body via sloughing 
of iron replete intestinal cells, bleeding and menstruation. The amount of replacement 
iron required varies from 0.5 milligrams to 2 milligrams depending on age and gender 
(Hoffbrand and Moss 2011). Iron deficiency occurs when the body fails to replace the 
required amounts, and this can be due to various factors discussed in section 2.2.1. 
 
2.2.1. Causes of iron deficiency 
 
Iron deficiency occurs when demand exceeds supply, and this can be due to various 
factors. In developing countries nutritional deficiency is a major cause of iron deficiency 
(WHO 2015) as well as hookworm infestation and Helicobacter pylori infection 
(Hoffbrand and Moss 2011). In nutritional deficiency, iron bioavailability is reduced 
even when the demand remains the same. On the contrary, reduced iron bioavailability 
in hookworm infestation or H. Pylori infection is due to increased demand. Other causes 
of iron deficiency also include blood loss, alcoholism and increased physiological 
demand such as in pregnancy. 
 
 
Nutritional deficiencies occur due to consumption of foods of low nutritional value and 
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this is common in developing countries where hunger and malnutrition are a common 
occurrence (Bailey et al., 2015; de Benoist et al., 2008; WHO 2011). Foods rich in iron 
include meat, fish and poultry products which are relatively expensive. Such foods 
are also not a priority when financial resources are constrained. Furthermore, animal 
and poultry products do not form part of a staple diet in developing countries where 
communal farming is the main form of income and livelihood. This causes of IDA 
usually occur over time because iron stores are gradually reduced due to an 
imbalance in iron uptake and iron loss. 
 
Parasitic infestation causes iron deficiency due to increased demand on iron because 
the parasites feed on the human body. The parasites in particular hookworms reside 
in the gastrointestinal tract which encourages sloughing of the cells they come into 
contact with. Obscure occult bleeding as well as gastrointestinal bleeding are common 
features in hookworm infestation. In such instances, iron is lost as haemoglobin 
contained in intact red cells. Blood loss in general causes iron deficiency because 
most of the iron in the body is depleted in trying to compensate for the blood loss. 
 
2.3. Impact of iron deficiency anaemia 
 
The effects of IDA on general health are wide and diverse with consequences that 
can span an individual’s entire life. Even though IDA is a nutritional disorder that can 
be transient, its consequences can be perpetuated across generations (Bailey et al., 
2015).  It is therefore imperative to manage this ailment as soon as it is diagnosed to 
prevent long-reaching untoward effects that can emanate from this disorder. The 
effects include impaired cognitive development, decreased productivity, and 
increased maternal mortality amongst other consequences. 
 
2.3.1 Functional consequences of iron deficiency anaemia 
 
Functional consequences are defined as the alteration of an individual’s actual or 
potential capacity to carry out tasks that are regarded as normal for their age (Kirch 
2008). Functional ability is influenced by cognitive development, muscle function and 
physical performance. 
 
An association between IDA and impaired cognitive development has been reported 
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(Black 2014). The Global Burden of Disease (2000) project confirmed that iron 
deficiency contributes to impaired cognitive development (Stoltzfus et al 2003). Other 
studies by Beltran-Navarro and their team concluded that the development of 
environmental sound perception and motor skills is affected by iron deficiency 
(Beltran-Navarro et al 2012). This is explained by the role of iron in brain development 
as enzymes that contain iron are involved in myelination of the neurons and formation 
of dendrites. The lack of iron disturbs the dendritogenesis and consequently neuronal 
development. The effect of iron deficiency in neuronal development is irreversible 
resulting in life long effects of impaired cognitive development such as low academic 
performances, anxiety and depression (Hlatswayo et al 2016).   
 
It has also been established that iron deficiency has a negative impact on an 
individuals’ productivity at work (Stoltzfus et al 2003). This is mainly due to the effect 
IDA has in reducing energetic efficiency and endurance levels. In separate studies, 
Denvir et al (2015) established a linear relationship between iron deficiency and 
physical activity. With decreased physical activity reduced productivity can be inferred 
especially in workplaces where physical activity is imperative such as in production 
factories. 
 
2.3.2 Maternal mortality in iron deficiency anaemia 
 
Two meta-analyses drawing upon the same published studies reported on an 
association between IDA and maternal mortality. Brabin et al (2001) suggested that 
there is an association between a higher risk of maternal mortality with severe 
anaemia. Stoltzfus and colleagues concurred with these findings suggesting that the 
risk of maternal mortality and haemoglobin levels have a non-linear relationship 
(Stoltzfus et al., 2005). 
 
A negative correlation between maternal IDA and gestation period is also well 
established (Allen, 2001). There are currently two widely accepted biological 
mechanisms that explain this phenomenon. One of the theories suggests that 
anaemia causes hypoxia to the unborn foetus. It further suggests that anaemia 
induces maternal and foetal stress leading to production of corticotropin-releasing 




Maternal iron deficiency is strongly associated with low birth weight and stunned 
growth (Stoltzfus et al., 2005). These effects are evident regardless of the presence 
or absence of anaemia. It is also pertinent to note that while full term infants are 
normally born with sufficient iron stores they may develop iron deficiency after birth. 
This is because infants have high iron requirements and the diets offered to them do 
not usually meet this demand.  
 
2.3.3. Implication of iron deficiency on red blood cell production. 
 
Iron is required for red blood cell production where it is incorporated into the haem 
molecule. The haem moiety combines with a globin chain, four of which make up a 
haemoglobin molecule which is the oxygen carrier molecule for red blood cells. 
 
During haem synthesis glycine combines with succinyl coenzyme A to form 
porphobilinogen. This biochemical reaction is catalysed by δ aminolaevulinic acid (δ 
ALA). Porphobilinogen goes through a series of biochemical reactions in the cytoplasm 
before returning to the ribosomes as protoporphyrin. Protoporphyrin combines with 
ferrous iron to form a haem molecule (Hoffbrand and Moss 2011). From this 
discussion, it is evident that reduction in iron levels has a direct impact on haem 
synthesis and subsequently haemoglobin production. In its initial stage, iron deficiency 
result in formation of red blood cells with reduced amounts of haemoglobin. These are 
referred to as hypochromic red blood cells. In conjunction with hypochromasia, the red 
cells are also smaller than normal and are referred to as microcytes. These features 
are present even before anaemia becomes evident. 
 
The production of microcytic hypochromic red blood cells is a compensatory 
mechanism to try and maintain normal erythropoietic activity in the absence of 
adequate iron supply. If the condition is not corrected, progressive decline in 
haemoglobin production occurs and eventually the patient becomes anaemic. Other 
red cell morphological features such as pencil shaped cells and target cells pursue. 
The formation of these abnormal red cell morphologies shortens the life span of the 
cells which further ameliorates the anaemia (Kempe et al., 2006) Abnormal red blood 
cells are removed and destroyed by the reticuloendothelial cells as the red blood cells 




2.4 Diagnostic strategies for iron deficiency anaemia 
 
The common strategies for diagnosing iron deficiency anaemia relies on the detection 
of low levels of bioavailable iron and decreasing haemoglobin levels. The amount of 
available iron can be assessed in different ways some of which are invasive. 
Haemoglobin determination however is usually carried out by performing a full blood 
count. A full blood count result is useful in determining haemoglobin levels as well as 
other parameters that are of diagnostic significance. 
 
2.4.1. Full Blood Count as an indicator of Iron deficiency anaemia. 
 
In Iron Deficiency Anaemia (IDA) a full blood count test result would show a reduced 
haemoglobin level below the set threshold for age and gender. 
Apart from a haemoglobin value, other parameters such as red cell indices and red 
cell morphological features are useful in diagnosing IDA. Relevant red cells indices are 
Mean Cell Haemoglobin (MCH), Mean Corpuscular Haemoglobin Concentration 
(MCHC), and Mean Corpuscular Volume (MCV). These three parameters give an 
indication of cell size and level of haemoglobinisation. The following ranges are 
regarded as normal for an adult: 
MCV: 80 - 95 femtoliters 
 
MCH: 27 - 34 picograms/cell 
 
MCHC: 300 - 350 grams/litre. (Hoffbrand and Moss, 2011) 
 
These values are a guide and every geographical location and laboratory usually 
establishes their own ranges suitable for the populace they serve.  An MCV below the 
lower limit of normal gives an indication of microcytosis and this is usually encountered 
in IDA and certain haemoglobinopathies. An MCHC below the lower limit of normal 
gives an indication of hypochromasia which again is an indication of inadequate 
haemoglobin and hence inadequate iron bioavailability. In this case Hepcidin values 
would give a better indication of iron status compared to MCHC values however 
Hepcidin is not part of a full blood count result. Mean corpuscular haemoglobin is a 
good indicator of hypochromasia and hence IDA. However, Thomas et al., (2013) 




From the FBC results, a diagnosis of microcytic hypochromic anaemia can be made. 
A peripheral blood film however needs to be examined in order to be more certain that 
IDA is present unless there is supporting clinical information. Common features for IDA 
that are found on a peripheral blood film include pencil cells and target cells. 
 
2.4.2. Iron levels as an indicator of Iron Deficiency Anaemia (IDA) 
 
Availability of iron is related to the presence of iron deficiency anaemia in all but a few 
cases. This is explainable by the fact that iron is essential in the early stages 
of erythropoiesis when it is incorporated to the haem molecule. For this reason, 
assessment of iron levels in the bone marrow has been made the gold standard test 
for iron deficiency anaemia (Johnson-Wimbley and Graham 2011). Other indicators of 
iron bioavailability include serum iron levels, serum ferritin levels as well as total iron 
binding capacity. Ferritin is the storage form of iron and a reduction in this parameter 
indicates reduction in stored iron and subsequently reduced iron bioavailability. Ferritin 
levels may however be misleading because it is affected by inflammation. 
Inflammatory conditions result in an increase in ferritin levels because it is an acute 
phase reactant (Clark 2009). The measurement of serum iron gives a better picture as 
it assesses the presence of both iron and ferritin when using the Ferrozine colourimetric 
method (CHRONOLAB n.d.). This method allows for iron in transferrin to dissociate 
first before being assayed together with other non-bound iron. 
 
2.4.3. Presence of stainable iron as a measure of iron bioavailability 
 
The gold standard method for assessment of iron bioavailability includes the 
demonstration of stainable iron in the bone marrow. This could be either a bone marrow 
aspirate or trephine biopsy but in both cases obtaining the sample is invasive and 
labour intensive. The bone marrow sample is stained with an iron stain such as Pearls 
Prussian blue stain. In iron deficiency anaemia little or no demonstrable iron is 
present in the bone marrow (Hoffbrand and Moss 2011). A closer look at the 
developing erythroblasts also show  absence  of  iron  and  the  presence  of  smaller 





2.5. Overview of the current diagnostic strategies for IDA. 
 
Generally diagnostic approaches are informed by guidelines and IDA is not an 
exception. Guidelines help to standardise the diagnostic approaches and they take 
cognisance of both current evidence as well as the cost implications of all the available 
options. 
 
2.5.1. Current guidelines 
 
Guidelines on diagnosis of anaemia rely on clinical symptoms, medical history as well 
as laboratory results. Clinical symptoms for anaemia in general include fatigue, loss of 
energy, pale skin and shortness of breath which is more evident during exercise 
(Hoffbrand and Moss 2011).  All these are a result of a reduction in the red blood 
cells’ oxygen carrying capacity brought about by a reduction in haemoglobin level or 
function. Medical history for a patient with anaemia will include lack of concentration 
and feeling tired all the time. These findings usually tie up with the clinical symptoms, 
but laboratory investigations are imperative for a diagnosis of anaemia, in particular 
iron deficiency anaemia, to be confirmed. 
 
Guidelines on laboratory diagnosis of iron deficiency anaemia vary in different 
parts of the world. They are however based on the same principles of observing the 
haemoglobin values with lower values being used to define anaemia. The threshold for 
defining anaemia however varies depending on locally agreed reference normal range 
values. In fact, Odhiambo et al., (2015) and Huma & Waheem  (2013)  commends  that  
the  establishment  of  local  reference  normal ranges is important in countering 
physiological variations due to differing demographics 
 
The presence of iron deficiency can be assessed in different ways, the most common 
of which are low serum iron values, depressed ferritin levels in serum, reduced iron 
stores in the bone marrow and red cell morphological features associated  with  
erythropoiesis  in  iron  deplete  states.  In  reduced  iron  levels, smaller than normal 
red cells are produced and inadequately haemoglobinised red blood cells are a 
common feature. The presence of pencil shaped red cells is also synonymous  with  
iron  deficiency.  Pencil  cells,  together  with  the  presence  of varying populations of 
red cell sizes gives rise to higher than normal red cell distribution width which again is 
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a pointer to iron deficiency anaemia. 
 
2.5.2. Namibian approach to diagnosis of iron deficiency 
 
Diagnosis of iron deficiency anaemia can either be straightforward or it could be marred 
by the presence of underlying medical conditions. Common medical conditions 
associated with iron deficiency anaemia include pregnancy and malnutrition.  
Pregnancy presents an increased demand due  to  the  nutritional needs  of  the  
developing  foetus.  Malnutrition results in reduced intake of iron among other 
nutrients. In all scenarios, the diagnostic approach for IDA is the same   according   
to the   Namibian   treatment   guidelines.   There   are   however differences in clinical 
presentations with some concurrent medical conditions masking the clinical features of 
IDA thus the treatment guidelines highlight the importance of laboratory testing, 
medical history and physical examination (MoHSS 2011). 
 
The diagnosis of anaemias in general is also guided by the Namibia standard treatment 
guidelines (MoHSS 2011).   Anaemia in this case is defined as a haemoglobin level 
below the lower limit of reference normal range and these ranges differ according to  
age and gender  (MoHSS  2011). Low haemoglobin levels and low Mean Corpuscular 
Volume (MCV) values indicate microcytic hypochromic anaemia of which iron 
deficiency anaemia belongs to this group of anaemias. Other microcytic hypochromic 
anaemias include haemoglobinopathies in which case a differential diagnosis is 
needed before iron deficiency anaemia is confirmed. In light of this, the Namibia 
standard treatment guidelines (MoHSS 2011) state that a full blood count should be 
done, and red cell indices looked at. Iron deficiency anaemia should be suspected if 
the MCV is low and further testing initiated to confirm its presence. 
 
The guidelines further suggest the use of a peripheral blood smear as well as iron 
studies to confirm the presence of iron deficiency (MoHSS 2011). Iron studies assess 
physiological iron bioavailability and peripheral blood smears assess the presence 
of  morphological  features  associated  with  iron  deficiency  anaemia. These 
parameters complement each other when carrying out a diagnostic workout for iron 
deficiency anaemia. These guidelines are in line with the UK guidelines on the 
diagnosis of anaemia. The UK guidelines suggest the use of the same parameters 
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including red cell indices such as MCV and Mean Corpuscular Haemoglobin 
Concentration (MCHC) (Thomas et al., 2013). 
 
This approach, although it works, can be improved by the introduction of Hepcidin 
testing. Hepcidin testing can complement other informative tests such as haemoglobin 
levels as well as replace other invasive tests that are used to assess presence of 
adequate amounts of iron. Invasive tests such as assessment of bone marrow iron 
stores and expensive tests such as iron studies could be streamlined once Hepcidin is 
introduced as a routine diagnostic test for the diagnosis and prognosis of IDA. Iron 
studies are a battery of tests which include serum ferritin, serum iron, transferrin and 
total iron binding capacity. The general shortfalls of the current approach include the 
need for a battery of tests to make a diagnosis for a simple disorder such as iron 
deficiency anaemia. The need for invasive tests such as  bone  marrow  biopsy  to  
assess  iron  stores  also  makes  it  an  expensive diagnostic approach requiring not 
only the laboratory staff but also clinical haematology staff who are, in most cases, 
consultant grade medical staff. 
 
2.5.3. Proposed approach 
 
With the introduction of Hepcidin testing it may be possible to streamline the diagnostic 
tests needed to identify iron deficiency anaemia. A full blood count result and 
Hepcidin test could be all that is needed for both the diagnosis and prognosis of IDA. 
A full blood count result gives parameters such as haemoglobin which  confirms  the  
presence  of  anaemia.  Other  parameters,  namely  red  cell indices such as Mean 
Corpuscular Volume (MCV) confirms microcytosis. Hepcidin can therefore be used 
to elucidate the cause of microcytic anaemia. Hepcidin levels below the lower limit 
of normal in a patient without medical history of chronic disease should be able to 
confirm IDA.  Hepcidin levels are suppressed in IDA and this study seeks to assess 
the magnitude of the level of suppression. In so doing Hepcidin levels from a reference 
normal range group were established and used to assess how the degree of Hepcidin 
suppression varies in IDA. 
 
Patients on treatment for IDA usually require a correction in red cell indices especially 
MCV to ascertain treatment success. Hepcidin has an immediate effect on iron levels 
(Rivera et al., 2005) in turn it is also more sensitive to iron bioavailability. It therefore is 
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a more sensitive prognostic marker. Therefore, IDA patients on iron treatment who 
demonstrate rising levels of Hepcidin should be considered as a positive outcome. 
This should be considered a treatment success even without evidence of repleted iron 
stores. 
 
Hepcidin could reduce lead time to diagnosis once a model is established that relates 
the dynamics of Hb with changes in Hepcidin levels. This will consequently make it a 
more sensitive prognostic indicator. Efforts to expand the current knowledge base on 
Hepcidin levels are therefore essential for this ultimate goal. This research work 
focuses on establishing normal ranges in the Namibian population as well as 
differentiating iron deficiency from non- iron deficient states using Hepcidin. 
 
In their work (Abosakran et al., 2014) established the correlation between red cell count  
and  Hepcidin  as  well  as  haemoglobin  and  Hepcidin  in  a  paediatric population. 
Takasawa et al., (2015) also performed correlation studies with MCV and Hepcidin 
r=0.20 albeit with a higher p value of 0.1655 which meant the results were not 
statistically significant. The same correlations can be done with other RBC indices. 
In this current study, correlations between Hb and Hepcidin were established for both 
the normal reference ranges population as well as for the IDA population. Correlations 
for Hepcidin with MCV, RDW as well as MCHC were also established with the intention 
of finding out more appropriate indices to use. The relationship between Hb levels and 
earlier Hepcidin concentration was also used to investigate the utility of Hepcidin in 
reducing lead time to diagnosis. Correlations between Hepcidin levels and change in 
haemoglobin concentrations (ΔHb) were also established in an attempt to strengthen 
the case for using Hepcidin as a predictor of response to iron supplementation. 
 
2.6. Introducing Hepcidin 
 
Hepcidin was first discovered in 2000 by Krause et al., (2000) in human blood 
ultra-filtrate and urine samples (Ganz 2003; Kemna et al., 2008; Politou et al., 
2004). It was originally called liver-expressed antimicrobial peptide (LEAP-1) because 
of its antimicrobial activity against some gram-positive Bacillus and Staphylococcus 
species as well as a Neisseria species, Neisseria cinerea which is a gram-negative 
bacterium (Krause et al., 2000). The anti-microbial activity of Hepcidin goes beyond 
the bacterium kingdom; it also shows anti-fungal activity against Saccharomyces 
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cerevisiae, commonly known as brewer’s yeast.  Tavanti et al., (2011) also 
demonstrated the anti-fungal effect of Hepcidin albeit Hepcidin 20, against Candida 
species and this goes on to show its broad antimicrobial properties over and above 
its role in iron metabolism. Since its discovery and the unearthing of its antimicrobial 
activity, it took a further year to confirm the existence of the link between Hepcidin 
and iron metabolism (Pigeon et al., 2001). The linkage forms the basis of this 
research work which looked at the behaviour of Hepcidin with reference to iron’s 
involvement in red blood cell production. The Hepcidin-iron linkage also further 
clarified the relationship between Hepcidin and some of the haematopoietic products 
such as red blood cells. 
 
Since its discovery, a lot of work has gone into characterising this molecule. The name 
‘hepcidin’ originated from the anatomical site of its synthesis as well as its anti-
microbial activity (Politou et al., 2004). The prefix hep-; is derived from the word 
hepatocytes which are liver cells and the suffix-cidin which is usually designated to 
antibiotics, emanates from the antimicrobial activity of the molecule. Hepcidin is 
synthesized mainly in the liver as pro-hepcidin, an inactive form of hepcidin (Ganz 
2011). Other organs have been known to produce hepcidin as well and these include 
the kidneys (Kulaksiz et al., 2005) and the heart (Isoda et al., 2010).  
 
Once produced, pre-prohepcidin is firstly converted to an inactive pro- hepcidin 
polypeptide which is then converted to an active Hepcidin molecule by a pro  protein  
convertase  enzyme  called  furin  which  cleaves  it  into  a  smaller molecule (Poli et 
al., 2014; Ganz et al., 2011). The smaller molecule is the active form of the hormone, 
hepcidin. Hepcidin is a polypeptide existing in three main isomer forms namely: 
hepcidin 25; hepcidin 22 and hepcidin 20. The isomers have 25, 22 and 20 amino acids 
respectively (Kenma et al., 2008).  
 
Hepcidin 25 and hepcidin 20 are detectable in human serum but all three isomers are 
present in urine samples (Campostrini et al., 2010; Kenma et al., 2008). Hepcidin 25 
is the major form of hepcidin responsible for iron regulation despite the presence of 
several isomers. Hepcidin 20 contains greater antimicrobial properties than hepcidin 
25 but does not have the ability to degrade ferroportin (De Domenico et al., 2008) a 
major drawback to its ability to regulate iron. This leaves hepcidin 25 as the major 
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regulator of Iron detectable in human blood. 
 
Formation of hepcidin is under the control of the hepcidin antimicrobial peptide (HAMP) 
gene which is located on chromosome 19q13 (Kenma et al., 2008). Its expression 
however is under the influence of many factors which include hemojuvelin 
(Papanikolaou 2004) High iron Fe (HFE) protein (Ahmad et al., 2002) and the Bone 
Morphogenic Proteins (Truksa et al., 2006). These factors play an important role in 
the signalling pathways that take place for hepcidin expression and they are 
discussed in section 2.6.1 below. 
 
2.6.1. Hepcidin signalling pathways 
 
Cell signalling pathways are indistinct, at times their activities depend on other 
pathways and this makes them even more complex. They do not function 
independently; instead they constitute complex pathways with which the effects of 
initial interactions are amplified on the next stages (Hancock 2010).   At present 
only two iron-related signalling pathways that are responsible for the expression of 
Hepcidin  have  been  established  and  these  involve  the  Bone  Morphogenetic 
Proteins (BMP) and the Transferrin Receptors (TFR) respectively (Knutson 2010). 
These  two  signalling  pathways  independently  upregulate  Hepcidin  expression 
when activated. There is however evidence to suggest that there is crosstalk that exists 
between the BMP and TFR signalling pathways. This demonstrates the high level of 
complex interactions that occur in these distinct signalling pathways. 
 
The BMPs regulate Hepcidin expression via the bone morphogenetic 
proteins/hemojuvelin/sons of mothers against decapentaplegic (BMP/HJV/SMAD) 
signalling pathway. BMPs are a group of about 20 molecules with hormonal properties 
and they include BMP1 to BMP15 with BMP6 being the key regulator of Hepcidin 
although this is yet to be demonstrated with human subjects (Andriopoulos et al., 2009; 
Meynard et al., 2009). Babitt et al., (2007) and Truksa et al’s (2006) work on BMPs 
established the link between the BMPs and Hepcidin expression. They were able to 
demonstrate that BMPs2, 4 and 9 are also able to regulate Hepcidin expression 
notwithstanding the fact that BMP6 is the main protein involved. Meynard et al‘s (2009) 
work which proved that systematically destroying  BMP6  in  mice  resulted  in  
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undetectable  levels  of  Hepcidin  also confirmed that BMP is a key regulator of 
Hepcidin expression. 
 
From the studies, it was also possible to infer that the BMP/HJV/SMAD pathway 
regulate Hepcidin expression in response to iron bioavailability. Figure 2.1 illustrates 




Figure 2.1: The BMP/HJV/SMAD pathway and the role of BMP receptors. 
Reproduced from: Muckenthaler M. U. (2014). How mutant HFE causes 
hereditary hemochromatosis Blood 124 (8):1212-1213 
 
 
Figure 2.1 above shows how Hepcidin expression is regulated by the interactions 
between TFR, Hfe, HJV and SMAD proteins. Hfe interacts with TFR2 to form a 
signalling complex together with HJV. The Hfe/TFR2/HJV complex binds to BMP 
receptors (labelled as I and II on the diagram in Figure 2.1) to avert being destroyed.  
The binding of the Hfe/TRF2/HJV complex to BMP receptors results in the increased 
presence of the BMP receptor on the cell surface. The BMP receptors allow for 
BMPs in particular BMP6 to attach thereby activating the signalling of hepcidin 




The BMP/HJV/SMAD signalling pathway can either be mediated by inflammation or 
iron, the latter being the relevant one in this study. In the iron mediated 
BMP/HJV/SMAD pathway, BMP6 binds to BMP receptors on the surface of the cell 
membrane. This interaction increases the phosphorylation of SMAD proteins which 
then translocate to the nucleus to upregulate transcription of Hepcidin (Core et al., 
2014; Mleczko-Sanecka et al., 2014). The interaction of the bone morphogenetic 
proteins with its receptors requires haemojuvelin as a co-receptor hence the name 
BMP/HJV/SMAD signalling pathway. 
 
The other major signalling pathway for Hepcidin is the Transferrin Receptors (TFRs) 
dependent signalling pathway which is illustrated in Figure 2.2. In this pathway the 
amount of available iron has an effect on whether Transferrin receptor 2 (TFR2) 
complexes with holotransferrin or not.   When there is low iron bioavailability, the 
amount of holotransferrin is reduced and consequently holotransferrin-TFR2 
complexing is minimal. Inversely, when there are increased levels of holotransferrin its 
complexing with TFR2 is increased and so is the extracellular signal-regulated kinases/ 



















Figure 2.2: Role of Transferrin receptors in regulating Hepcidin expression in 
iron deplete (A) and iron replete (B) states. The TFR/MAPK signalling pathway 
as illustrated by Lawen A., Lane D. J. R. 2013.  Mammalian Iron Homeostasis in 
Health and Disease: Uptake, Storage, Transport, and Molecular Mechanisms of 
Action Antioxidants & Redox Signalling: 18 (18): page 2489 
 
 
In the TFR pathway, binding of TFR2 with Hfe results in the phosphorylation of 
mitogen activated protein (MAP) kinases and their translocation to the nucleus. Once 
they reach the nucleus these activated MAP kinases will subsequently activate 
Hepcidin transcription and consequently its expression (Hancock 2010; Knutson 
2010). 
 
Studies by Kawabata et al., (2005) and Nemeth et al., (2005) indicated that TFRs, in 
particular transferrin receptor 1 (TFR 1) and transferrin receptor 2 (TFR2), are 
important in regulating the expression of Hepcidin. This observation can be explainable 
on the basis of the interaction of TFRs, High iron gene (Hfe) and Transferrin, in 
particular holo transferrin (Knutson 2010). Gao et al’s (2009) studies also revealed that 
iron saturated transferrin (holo transferrin) plays an important role in TFR2 mediated 
Hepcidin production. The interaction between Hfe and TFR2 upregulates Hepcidin 
expression, furthermore Hfe is also able to interact with TFR1. TFR1’s binding sites 
for holo transferrin and Hfe overlap (Schmidt et al., 2008). 
 
 
In their model, Schmidt et al., (2008) supports the notion that Hfe, holo transferrin, 
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TFR1 and TFR2 form a signalling complex that regulates Hepcidin expression 
based on the type of interactions at any particular time. In low Iron states where 
holo transferrin is inadequate most of the Hfe is sequestered in TFR1 preventing its 
interaction with TFR2 and consequently reducing the signalling for Hepcidin 
expression. In Iron replete states the levels of holo transferrin are greatly increased. 
This in turn increases holo transferrin and Hfe competition for the TRF1 binding sites 
with the resulting increase in available Hfe for TFR2 binding and consequently 
increased signalling for Hepcidin expression. 
 
Additionally, Hepcidin inhibits TFR expression thereby inhibiting iron transportation. In 
their work, Du et al., (2011) demonstrated that Hepcidin directly reduces the expression 
of TFR albeit TFR1 in this case. They concluded that Hepcidin controlled iron uptake 
and release by regulating the expression of TFRs and other iron transport proteins 
(Du et al., 2011). It is pertinent to note that the action of Hepcidin on intracellular 
Iron transportation is two-fold. Through its interaction with TFRs and Divalent Metal 
Transporters (DMTs), Hepcidin regulates intracellular iron uptake. On the other side 
it interacts with ferroportin to regulate iron release from the iron rich cells namely 
macrophages and intestinal epithelial cells. 
 
2.6.2. Hepcidin structure 
 
Hepcidin is a polypeptide which in its mature form can contain up to 25 amino acids 
(Krause et al., 2000). The mature forms of Hepcidin originate from an 84-amino acid 
long precursor known as pre-prohepcidin (Clark et al., 2011). This polypeptide, 
Hepcidin, is folded into an irregular shape held together by four disulphide bonds 
according to earlier work by Krause et al., (2000).   These disulphide bonds link the 
eight cysteine molecules found in the Hepcidin polypeptide (Krause et al., 2000). The 
disulphide bonding pattern appear to be constant in all animals capable of producing 
Hepcidin (Nemeth et al., 2006) and more recent work by Jordan et al., (2009) further 
elucidated that the Hepcidin molecule forms a hair like structure. The structure exists 
in two forms depending on the  thermal  conditions.    Figure  2.3  shows  the  two  
different  structures  of Hepcidin as elucidated in Jordan et al’s (2009) work. The N 
terminal end shown below is essential for biological activity and its interaction with 





Figure 2.3: An illustration of Hepcidin structures at different temperatures. 
Reproduced from Jordan  J.B., Poppe  L., Haniu  M., Arvedson  T., Syed  R., Li  
V., Kohno  H.,Kim  H., Schnier P.D., Harvey  T.S.,  Miranda L.P., Cheetham J., 
Sasu B. J. (2009). Hepcidin revisited disulphide  connectivity, dynamics, and 




















The figure above shows two forms of the three-dimensional structure of Hepcidin A & 
C at high temperatures and B & D at low temperatures. The four disulphide bonds 
illustrated above are important for its interaction with ferroportin, to this end it has 
been demonstrated that cross species Hepcidin ferroportin interactions are  possible  
(Nemeth  et  al.,  2006).  This has however posed challenges in assay development 
as cross species immune recognition of the Hepcidin antigen has a bearing on 
provocation of immune responses in host animals. 
 
2.6.3. Mechanism of Hepcidin action 
 
Despite its antimicrobial action, Hepcidin is known as an iron regulatory hormone and 
its activity is closely related to its interactions with iron transport proteins.  Its role in 
iron metabolism can be inferred from Pigeon et al’s (2001) work where it was observed 
that its  synthesis  can  be  induced  by  dietary  iron.   
Hepcidin down regulates ferroportin by regulating its post transcriptional expression 
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and by degrading expressed ferroportin (Nemeth et al., 2004). These interactions block 
iron transport from the iron rich cells thereby reducing iron bioavailability. It is pertinent 
to note that ferroportin is present in cells such as hepatocytes, reticuloendothelial 
macrophages as well as placental tissue. These are the active sites for the movement 
of iron and contribute significantly to its bioavailability. The interaction between 
Hepcidin and ferroportin on the plasma membrane results in the formation of a 
Hepcidin-ferroportin complex. The interaction is thought to involve biochemical 
reactions where sulphur anions are exchanged between the disulphide bonds of both 
Hepcidin and ferroportin (Qiao et al., 2012).This complex is internalised by a process 
called Hepcidin induced endocytosis. The internalisation results in the reduction in the 
number of available ferroportin molecules on the plasma membrane surface for iron 
exportation. 
 
After the process of endocytosis, the Hepcidin-ferroportin complexes are then 
degraded  by  tyrosine   phosphorylation   and   ubiquitination   of  the   Hepcidin- 
ferroportin complex (de Domenico et al., 2007; Qiao et al., 2012). In their work, de 
Domenico  et  al.,  (2007)  demonstrated  that  the  attachment  of  Hepcidin  to 
ferroportin  triggers  phosphorylation  of  ferroportin  and  this  takes  place  at  the 
plasma membrane. Once phosphorylated, the complex is internalised into the 
cytoplasm  where  it  is  dephosphorylated  and  subsequently  ubiquinated. Ubiquinated 
ferroportin is then transported to the lysosomes where it is degraded, and this 
concludes the fate of both ferroportin and Hepcidin in this interaction. 
 
 
2.7. Hepcidin and iron metabolism 
 
 
Iron movement involves its uptake into the cells, in particular apical cells of the 
intestinal epithelium, and its release into plasma. Iron uptake is usually through 
absorption of dietary iron from the intestine. Absorption of iron occurs at a smaller scale 
in comparison to the average daily intake of dietary iron, thus most of the iron just 
passes through the gastrointestinal tract and is excreted through faecal matter. This 
can be attributed to the fact that the body does not have a defined physiological 
mechanism of disposing of iron once it is absorbed. Iron absorption therefore only 
occurs to replace iron lost due to normal sloughing of cells of the gastrointestinal track, 
menstrual blood loss and occult blood loss all of which have minimal effect on total 
available body iron. As a result, only 1 to 2 milligrams of iron needs to be replaced on 
40 
 
a daily basis (Hoffbrand and Moss 2011). The iron requirements are much increased 
in pregnancy due to the demands attributable to foetal growth and an increase in 
maternal red cell mass. 
 
Dietary iron occurs as either haem iron or non-haem iron. Meat is the main source of 
haem iron whereas vegetables and plants are the main sources of non-haem iron. The 
iron absorption into the cells of the intestinal lumen is facilitated by a transmembrane 
protein called Divalent Metal Transporter (DMT). Acidic conditions in the intestine 
help to maintain the solubility of ferric iron (Fe3+). These Fe3+ molecules  are  then  
reduced  by  ferrous  ions  (Fe2+)  by  the  action  of  a  ferric reductase enzyme (Kaplan 
& Ward 2013).  Once reduce the ferrous ions are then transported into the cell cytosol 
by the DMT. Once absorbed into the cells, the iron’s release or export from the cells is 
regulated by another transmembrane protein called ferroportin. 
 
Ferroportin is the only mammalian Iron exporter known so far (Totorsa et al., 2016) 
thus its role as a major iron transporter makes it solely responsible for regulating iron 
bioavailability. Hepcidin, in particular Hepcidin 25, acts directly on ferroportin by 
degrading and internalizing this protein, a relationship which links Hepcidin activity to 
iron bioavailability. There is a direct relationship between Hepcidin expression and iron 
levels and the first study to demonstrate this link was performed by Pigeon et al., 
(2001). Hepcidin levels are reduced in response to low iron stores and this allows more 
iron to either be released from macrophages or absorbed from the intestines (Collins 
et al., 2008; Nemeth & Ganz 2009) when iron levels are high there is a consequential 
increase in the levels of Hepcidin (Collins et al., 2008; Nemeth & Ganz 2009). It is for 
this reason that Hepcidin plays a role in anaemias associated with iron metabolism. 
 
2.7.1. Hepcidin –ferroportin interaction 
 
Ferroportin is the only exporter of iron in mammals (Donovan et al., 2005; Totorsa et 
al., 2016), in their review, Kaplan and Ward (2013) also alluded to the fact that it is 
essential for the distribution of iron between tissues. Ferroportin is responsible for  
externalization  of  iron  from  iron  replete  cells  such  as  macrophages, 
hepatocytes and intestinal epithelial cells. On the other hand, Hepcidin is the only 
known receptor for ferroportin (Poli et al., 2014; Ramey et al., 2010). These attributes 
for Hepcidin and ferroportin, coupled with the unique relationship between Hepcidin 




In their work, Nemeth et al., (2006) demonstrated that Hepcidin-ferroportin interaction 
is reliant on the full functionality of the N-terminal end of the hepcidin polypeptide. They 
also highlighted that disulphide bonds are formed when the interaction is formed 
(Nemeth et al., 2006). Their later work on disulphide bonds and  Hepcidin-ferroportin  
interaction  further  elucidated  that  all  four  disulphide bonds on the Hepcidin molecule 
may be involved in the disulphide bond exchange with ferroportin (Clark et al., 2011) 
 
The presence of Hepcidin inhibits the iron export action of ferroportin by destroying it 
using the mechanisms that have been described earlier in section 2.1.3. This results 
in the internalization of iron and subsequently reduced extracellular iron. 
 
2.8. Hepcidin and Human disease 
 
Some human diseases can be linked to the way by which Hepcidin is regulated. 
Knowledge on the behaviour of this hormone is therefore important in trying to elucidate 
the pathophysiological mechanisms of disorders associated with abnormal   iron-
Hepcidin   interactions.   Hepcidin   is   directly   involved   in   iron interactions and is 
itself regulated by iron bioavailability as well as hypoxia and erythropoietic activity 
(Piperno et al., 2009). In normal physiological states, Hepcidin production is up 
regulated by increased iron stores and inflammatory conditions. This is in an attempt 
to normalise iron availability. On the other hand, Hepcidin production is down regulated 
by anaemia and any physiological consequences of anaemia such as reduced tissue 
oxygen availability and increased erythropoietic activity. This again is in an attempt to 
maximize iron bioavailability in an effort to correct the anaemic state. 
 
2.8.1. Hepcidin deficiency 
 
Hepcidin deficiency can be due to inadequate production, increased destruction or 
structural defects within the Hepcidin molecule. Inadequate production can be due to 
genetic defects within the Hepcidin gene or the regulators of Hepcidin expression.  
Genetic  aberration  in  HJV,  Hfe  or  TFR  expressions  can  lead  to reduced Hepcidin 
production and ultimately Hepcidin deficiency (Du-Thanh et al., 
2011). In such instances ferroportin is overexpressed leading to unregulated increase 
in dietary iron absorption. In macrophages and intestinal duodenal cells iron is over 
exported resulting in depleted intracellular iron as well as increased extracellular 
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iron. The presence of large amount of extracellular plasma iron saturates the iron 
transporter, transferrin. Once transferrin is saturated it leaves some iron unbound, 
which finds its way to the liver, heart and other endocrine organs. The liver cells have 
limited capacity for iron export (Ganz & Nemeth 2012) consequently iron accumulation 
in the liver is evident before other organs. 
 
Genetic defects within the Hepcidin gene, the HAMP gene, can cause structural 
changes within the Hepcidin molecule which have an effect on its interaction with 
ferroportin. In such cases ferroportin degradation and/or internalisation is not effected 
leading to unregulated iron export from the cells. Unregulated iron export consequently 
results in systemic iron overload and conditions associated with increased iron 
bioavailability. 
 
2.8.2. Hepcidin excess 
 
Hepcidin excess could be due to overstimulation of hepcidin synthesis or reduced 
clearance of normally produced hepcidin. Both scenarios are pathological states or 
occur as a result of manipulated iron metabolism such as in transfusion iron    
overload. Blood transfusion results in transitory increase in iron stores. This increase 
causes excess hepcidin production as a compensatory mechanism to counter the 
increased iron bioavailability (Nemeth et al., 2006a) 
 
In kidney disease renal clearance of hepcidin and other metabolites is reduced due 
to decreased kidney function resulting in increased hepcidin levels. Kidney disease 
results in reduced glomerular filtration and it may also be accompanied by inflammation 
which in itself is a positive regulator for hepcidin synthesis. It is important to note that 
hepcidin overexpression as a result of excess hepcidin results in reduced iron 
bioavailability (Nemeth and Ganz 2009).   This will subsequently result in reduced 
haemoglobin synthesis, a condition known as anaemia of inflammation. 
 
2.9. Summary of the aims of the study 
 
This study aims to assess the clinical usefulness of Hepcidin as a routine test in 
diagnosing iron deficiency anaemia. The assessment is done by appraising the current 
diagnostic approaches with Hepcidin assay on participants deemed to be having iron 
deficiency anaemia. The study also aims to assess the predictive value of Hepcidin in 
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patients on iron treatment for iron deficiency anaemia. In order to fulfil the above stated 
aims it is essential to establish baseline Hepcidin values to refer to in a Namibian 
context. This study therefore aims to establish the reference normal range in an adult 
population in Namibia. The normal adult population in this context is defined by the 
NaMBTS donation criteria. Under these criteria, only donors over the age of 16 years 
are allowed to donate blood (MoHSS, 2010). Participation in research by eligible 
donors between the age of 16 and 18 years requires parental consent in Namibia. 
Donors in this age group would present logistical complications to recruit.  Donors 
qualifying to donate blood are regarded as normal healthy adults; a discussion on this 





































The aim of this research was to investigate how Hepcidin testing can help to improve 
the diagnosis of Iron Deficiency Anaemia (IDA) and ultimately improve its 
management. This has been prompted by the high prevalence of this ailment in 
developing countries.  In order to fulfil this aim, specific objectives including 
establishment of reference normal values for Hepcidin and characterisation of the 
quantitative behaviour of Hepcidin in iron deficiency anaemia were set. 
 
Establishment of reference normal values required the use of blood samples from 
healthy normal adults. In contrast, an investigation on the quantitative behaviour of 
Hepcidin in anaemia required blood samples from individuals with iron deficiency. The 
laboratory experiments for full blood count, Hepcidin and serum iron were however the 
same. The research design and experimental methods to address the two objectives 
were similar in many ways. There were however some unique features in the 
populations under study thus the designs are discussed in separate sections. 
 
3.2.  Establishing reference normal values for the Namibian population 
 
Hepcidin testing is not currently being performed in routine diagnostic laboratories. 
Introducing this biomarker into the diagnostic arena requires the establishment of 
reference normal ranges adjusted for age and gender. Pasricha et al., (2011) 
established reference normal ranges for Hepcidin as <5.4 ng/mL to 174.6ng/mL in 
healthy premenopausal women in Australia. Galesloot et al., (2011) also established 
normal ranges for Hepcidin in the Netherlands. The later were divided according to 
gender and age in strata of 5 years each. The more recent work on Hepcidin reference 
normal ranges was performed in Greece by Sdogou et al., (2015) and it provided useful 
information relevant to the Greek population albeit for the paediatric populace. 
Appropriate reference normal ranges are required for accurate diagnosis and 
prognosis of disease, however, for Hepcidin most of this work has been performed 
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outside Africa South of Sahara. It is therefore justifiable to carry out the same work in 
an African context given the differing geographical locations and ethnicity 
compositions. 
 
The establishment of reference normal ranges in Namibia form the baseline and 
reference point for studying quantitative characteristics of Hepcidin. Establishing these 
ranges in Namibia also gives an opportunity to compare them with already established 
data on normal ranges elsewhere. The other importance of locally reputable reference 
normal ranges is the possibility of establishing Hepcidin-Hb correlations of which the 
data can also be compared to the same correlations found elsewhere. Sampling for 
normal healthy adults was done among the blood donor population.  
 
3.2.1. Sampling and sample size calculations for determination of reference 
normal values. 
 
Normal healthy blood donors were used to establish reference normal ranges. Healthy 
individuals were defined according to the donation criteria as set out by the NaMBTS. 
The donation criteria states that individuals should be between the age of 16 and 65 
and in good health for them to be able to donate blood (MoHSS 2010). It also states 
that they should have the following attributes: 
• No recent alcohol intake to an extent that someone is deemed 
legally unfit to drive or operate machinery. 
• Prospective donors should weigh more than 50kg. This 
attribute protects donors from developing anaemia of 
transfusion. 
• There should be no clinical evidence of bacterial infection on 
presentation. Blood transfusion carries a risk of bacterial 
contamination. Excluding prospective donors with such 
infections therefore reduces the risk of bacterial contamination. 
• Leading a sexually safe life style by practicing safe sex Safe 
sex practices includes the use of protection and having one 
partner at a time. 
• Are committed to helping others and will therefore donate for 
the right reasons (MoHSS 2010). 
The profile of a blood donor in general is consistent with a healthy individual and it 
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suffices to say blood donors are a good representative of a healthy population. 
 
The initiative by the NaMBTS to recruit Voluntary Non-Remunerated Donors (VNRD) 
makes it possible to use this population to establish reference normal ranges. These 
VNRDs are conscious of their contribution to society and they generally have good 
healthy habits making them a better target than randomly selecting individuals outside 
of a healthcare establishment. VNRDs give blood freely and voluntarily without 
expecting anything in return (WHO, 2012). Research by Kalargirou et al., (2014) 
established that the majority of these donors donate blood out of their unselfish 
concern for the welfare of others. These attributes are good features that contribute to 
the general wellbeing of an individual. They also demonstrate the appreciation of health 
for both self and others. 
 
In their work, Sdogou et al., (2015) carried out physical examinations on their 
participants to help ascertain their health status. In this research, the NaMBTS 
procedures as stated in their guidelines on donor selection (MoHSS 2010) were used. 
The procedures include checking for vital signs such as blood pressure, weight as well 
as asking questions about the donors’ general health using a standard donor 
questionnaire. The donor questionnaire elicits for information on an individual’s 
health and medical history of which some certain criteria has to be met before being 
allowed to donate blood.  
 
The approach on using donor questionnaires is similar to what Galesloot et al’s (2011) 
research used where they employed a health and lifestyle questionnaire as one of their 
participant selection tools. These approaches ensure that the participants’ health 
status is assessed based on clinical presentation on the day of blood sample collection 
as well as relevant medical history. This holistic approach minimises confounding 
variables such as hidden medical conditions that interfere with the physiological 
mechanisms involved in Hepcidin metabolism. Given that Hepcidin is sensitive to 
certain medical conditions such as bacterial infections, it is important to exclude them. 
 
On that premise individuals who qualified to donate blood were therefore included in 
the study. Deferral, whether permanent or temporary, was one of the exclusion criteria 
the basis of which was its perceived deviation from how “normal healthy” adult is 
defined. Non-consenting participants were also excluded as it is ethically immoral to 
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coerce anyone to participate in research studies. The other inclusion/exclusion criteria 
are tabulated in Table 3.1. 
 
Table 3.1: The Inclusion and exclusion criteria for participants enrolled in 
determining the normal range for Hepcidin in the Namibian population. 








• Samples from healthy donors who are allowed to donate 
 
at the time of joining the study. 
 
• Samples from apheresis donors donating platelets. 
 
• Samples from stable regular blood donors attending the 
blood  donation  sessions  for  the  purpose  of  donating 
blood. 








• Samples from donors who have features suggestive of 
 
Iron deficiency anaemia such as a low haemoglobin and 
low serum iron levels. 
• Samples from non- consenting participants. 
 
• Samples collected from individuals not donating blood. 
 
• Samples from participants who are therapeutic donors. 
 
 
The inclusion and exclusion criteria for this study were heavily informed by the MoHSS 
guidelines and were able to exclude donors with conditions that might interfere with the 
establishment of reference normal va lues for Hepcidin. These included donors 
with low haemoglobin levels as well as those with recent bacterial infections. Bacterial 
infections are known to upregulate Hepcidin expression and consequently reduce iron 
bioavailability (Armitage et al., 2011). Such participants will invariably exhibit higher 
Hepcidin levels. Excluding donors with recent infection is therefore mandatory for 
reference normal range values to be a true reflection of the normal healthy population. 
 
After establishing the inclusion criteria, a sample size calculation was performed using 
a sample size calculation for quantitative variables obtainable from cross sectional 
studies. The formular for sample size calculation is shown below and has been 









Where:         Z1-α/2 = standard normal variate 
 
SD= standard deviation. The SD value is obtainable from previous 
work. 
 
d= absolute error or precision. 
 
The standard normal variate used in this study is 1.96 using 5% type 1 error (P<0.05) 
and the desired absolute error/precision (d) of 6ng/ml. The desired absolute error was 
selected taking into consideration the performance characteristics of the CUSABIO® 
(n.d.) ELISA kit. The kit has a detection range of 4.69ng/mL-300ng/mL and a minimum 
detectable dose of less than 1.17ng/mL. 
 
The standard deviation was obtained after examining the literature with similar studies 
such as the work of Sdogou et al., (2015), Pasricha et al., (2011) and Galesloot et al., 
(2011). An SD of 18.94ng/ml was used. 
 





A sample size of 40 was therefore used to establish the normal range for Hepcidin 
using the blood donor population without partitioning for age and gender. 
 
3.2.2. Ethical issues 
 
Before embarking on this project approval was sought and obtained from the University 
of Bath through the Research Ethics Approval Committee for Health (REACH). The 
REACH reference numbers pertaining to this work are EP 14/15 237 – for when the 
project was initially reviewed and EP 15/16 20 – for when the project was approved. 
In Namibia permission to carry out research work and ethical clearance was also 
sort and granted from the Namibian Blood Transfusion Service before any work could 
be carried out. A copy of the approval letter is attached as Appendix 2. The Namibia 
Blood Transfusion Service has a mandate from the Ministry of Health and Social 
Services in Namibia to carry out research on blood  transfusion  practice  and  blood  
transfusion  related  work.  This  research looked at anaemia which has a direct link to 
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the activities of the NaMBTS as an establishment. The participants were also 
recruited from the NaMBTS therefore the application for ethical approval had to be 
directed to the NaMBTS. Another application to conduct research in Namibia was also 
sought from The Ministry of Health and Social Services. Permission was granted 
and copy of the approval letter from the MoHSS is attached as Appendix 3. 
 
Written informed consent was obtained from all blood donor participants and samples 
were collected into tubes containing Ethylene Diamine Tetra-acetic Acid (EDTA) as an 
anticoagulant and another set into serum separator tubes (SST) which do not contain 
an anticoagulant. Samples in the EDTA tubes were used to perform a full blood count 
and those in SST were used to assay for Hepcidin and serum iron levels. The blood 
donors were presented with a participant information sheet during the donation 
sessions. Both the participant information sheets and consent forms were presented 
in two languages namely English and Afrikaans. The participant information sheets 
(copies attached as Appendices 4 and 5) provided information on the relationship 
between Hepcidin and Iron. It also had useful information on iron deficiency anaemia 
and all the information was written in a language that a layperson would understand. 
The prospective participants were given the opportunity to read and ask questions on 
the content of the information sheet. Questions raised from the information sheet 
were answered by the nursing staff in the first instance and only escalated to the 
primary researcher when the nursing staff could not address them fully. 
 
Once the prospective participants were satisfied, they were given consent forms to 
complete before blood samples were taken. The consent forms documented 
information such as the participant identification number and the numbers used were 
the donation numbers which corresponded with the sample number. Both the 
participant consenting to take part and the person taking consent were required to sign 
after going through the consent form. The English and Afrikaans version copies of the 
consent forms are attached as Appendices 6 and 7 respectively. The patient 
information sheets as well as the consent form were provided in Afrikaans to cater for 
participants who were more comfortable with this language. Namibia uses English as 
the official language but has a significant size of native Afrikaans speaking individuals. 
 
Any adverse effects of blood collection were dealt with in the same manner as adverse 
effects for blood collection procedures of which are part of the NaMBTS standard 
operating procedures. The NaMBTS is an establishment which deals primarily with 
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blood collection, processing and distribution thus the nursing staff are conversant with 
procedures to follow when there are any signs of untoward effects of blood collection. 
This staff group was the same group that assisted in blood sample collection for this 
study. 
 
3.2.3. Data collection for use in determining the reference normal values 
 
3.2.3.1. Sample collection 
 
Venous blood samples were collected from consenting healthy blood donors by the 
NaMBTS nursing staff. Before blood collection, participants’ weight and vital signs 
such as blood pressure were determined to ensure they were safe to give blood. 
Normal phlebotomy procedures were followed as described in the WHO guidelines on 
phlebotomy procedures (WHO 2010). The participants were made to sit in a chair in a 
quiet and comfortable environment and a tourniquet was applied on the arm. The 
tourniquet makes it easy for the phlebotomist to identify the vein to use for blood 
collection. Once the vein was identified the venepuncture site was disinfected with an 
alcohol based disinfectant and allowed to dry before inserting the blood collection 
needle. The blood collection needle was inserted, and blood collected into vacutainer 
tubes containing EDTA as an anticoagulant and another sample into an SST tube. Two 
samples in total were collected from each consenting participant and were used to 
perform full blood count, Hepcidin and serum iron assays. 
 
The participants then proceeded to donate blood after samples for the Hepcidin 
study were collected. This order of events was important in order to avoid variation in 
Hepcidin concentrations caused by changes in blood volumes post blood donation. 
Hepcidin values respond to decrease in blood volume because of the consequent 
reduction in iron content (Collins et al., 2008). The samples were also collected from 
donors presenting at the NaMBTS for donation in the morning in order to minimise 
the effects of diurnal variation in Hepcidin (Kroot et al., 2009). The timing of collections 
was also important in optimising sampling conditions and it also became pertinent to 
standardise preparation of samples for laboratory analysis. 
 
3.2.3.2. Measures to ensure sample validity 
 
Two sets of samples were collected at a time, one for the Full Blood Count (FBC) test 
and the other sample for the Hepcidin and serum iron assay and any other assays 
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related to this study. The samples for FBC were collected in an EDTA anticoagulant 
which prevents clotting while preserving the morphology of the cells. The samples used 
for Hepcidin and serum iron were collected in a serum separator tube (SST) which 
does not have any anticoagulant.   The samples for FBC test were taken to the 
laboratory where they were processed on the same day. Samples for FBC need to be 
tested as soon as possible because storage, regardless of conditions, affects the 
different parameters of FBC results. This is in line with the recommendations and 
advice from different authors who have done some work on FBC results and storage 
conditions (Turhan et al., 2011; Cornet et al., 2012). 
 
The second set of samples that were collected in SST tubes were kept in the 
refrigerator at 2-8oC at the Namibia Blood Transfusion Service awaiting collection and 
transportation to the laboratory for processing. In the laboratory the samples were 
centrifuged at 1000g for 15 minutes according to the kit manufacturer’s instructions 
(CUSABIO®  n.d.). The samples were then aliquoted and frozen at - 70oC to avoid 
loss of bioactivity of the Hepcidin molecules. All samples were stored for at most 
2 months before testing in line with the guidance from the Hepcidin kit manufacturer 
(CUSABIO® n.d.) ELISA Kit). Storing samples for longer than 2 months is not 
recommended as it can result in the degradation and denaturalisation of the Hepcidin 
protein. The storage conditions were monitored closely both at the NaMBTS as well as 
in the testing laboratory. At NaMBTS the fridges are monitored to ensure records are 
generated to support the cold chain initiative as dictated by the NaMBTS 
establishment. At the testing laboratory the freezer temperatures were monitored as 
part of the routine monitoring exercise, records of which are stored and archived as 
per standard operating procedures in place at the Namibia University of Science and 
Technology (Blaauw, 2016). 
 
On the days of the experiments samples were thawed and allowed to reach room 
temperature before being assayed. All the other reagents were also brought to room 
temperature as per the manufacturer’s guidance. Once thawed the samples were spun 
down at 1000g for 5 minutes. All reagents were prepared according to the assay 
procedure (CUSABIO® n.d.) and an ELISA was set up. 
 
Samples for the Hepcidin assays were also used for assessing serum iron levels. 
Serum iron results were obtained to confirm the presence of normal iron levels in this 
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group. On the day of analysis samples were thawed and working reagents were 
prepared immediately prior to use to ensure the validity of the assay is not 
compromised. The thawed serum samples were spun at 1000g for 5 minutes to 
remove any insoluble particles that might interfere with spectrophotometric 
characteristics of the coloured complex when reading the absorbance of the final 
solution. According to the kit insert, samples needed to be separated as soon as 
possible. This was consistent with the requirements of the Hepcidin assay protocol 
therefore the same sample preparation protocol was sufficient to ensure sample 
validity. 
 
Assessment of sample integrity was paramount and factors such as haemolysis 
were used to exclude the sample for analysis. Haemolysis results in release of iron 
from red blood cells and subsequent increase in serum iron levels (Hoffbrand and Moss 
2008). Samples for serum iron as well as Hepcidin assays were only collected in the 
morning to minimise the effect of diurnal variation on these two analytes. 
 
Reagents  for  the  serum  iron  assay  were  protected  from  light  and  left  over 
prepared solutions were kept for not more than 3 months in the refrigerator at 2-8oC 
according to the reagent manufacturer’s instructions set out in the serum iron kit 
insets. A copy of the kit insert is included as Appendix 1. 
 
3.2.3.3. Hepcidin and serum iron assays 
 
The Hepcidin assays were run using an ELISA technique with a detection range of 
4.69ng/ml-300ng/ml. The inter assay and intra-assay precision for this assay was 
<10% and <8% respectively (CUSABIO® n.d.). The intra-assay Precision was 
performed by the kit manufacturer. This was carried out using three samples of 
known Hepcidin concentration. The samples were tested twenty times on one ELISA 
plate and the results used to assess intra assay precision (CUSABIO® n.d.). The 
inter-assay Precision to determine Precision between assays was also performed by 
CUSABIO® who are the kit manufacturers. On this instance three samples with a 
known concentration of Hepcidin were tested in twenty assays and the results used to 





3.2.3.4. Hepcidin ELISA assay  
 
The principle of the assay used is based on the quantitative sandwich enzyme 
immunoassay technique as described in the Hepcidin kit insert (CUSABIO®  n.d.) 
ELISA Kit). The principle is as follows: Microtiter plates with wells that are pre-coated 
with anti-hepcidin 25 antibodies are used. The pre-coated antibodies in the wells 
specifically react with hepcidin 25 antigens in the sample to form an antigen- antibody 
complex.  The reaction is  washed  to  remove  any  unbound  material leaving the 
complexes attached to the surface of the microtiter plate wells. 
 
After removing any unbound material, an anti hepcidin 25 antibody conjugated to biotin 
is introduced. The conjugated anti Hepcidin antibody react with the available antigenic 
determinants on the hepcidin 25 molecule. The mixture is washed to remove any 
unbound material before avidin conjugated Horse Radish Peroxidase is  introduced  
into  the  wells  of  the  microtiter  plate.  Addition  of  an  enzyme conjugated to avidin 
allows for the binding of    biotin with avid to form a stable interaction. The final 
complex has the ability to act on a substrate because of the presence of the enzyme 
Horse Radish Peroxidase (HRP). 
 
The peroxidase enzyme acts on the substrate to produce a coloured product. The 
reaction takes place at 37oC for 15-30minutes. In this assay the time was set at 30 
minutes in order to standardise the protocols. This duration was chosen as the standard 
incubation time as it allowed maximum time for the reaction to complete. After the 
incubation period, a stop solution is added to stop the reaction and intensity of the 
colour formed is measured at 450nm. According to Beer Lambert’s law, the intensity 
of the colour so formed is proportional to the concentration of the substrate, in this 
context the concentration of hepcidin 25 in the blood sample. This was obtained 
from a standard curve which was constructed using Hepcidin standards supplied by 
the kit manufacturer. 
 
There are several methods to quantitate hepcidin which include the ELISA, Mass 
Spectrometry (MS), High Performance Liquid Chromatography (HPLC), Radio 
Immunoassays (RIA), a n d  other novel approaches such as Surface-Enhanced Laser 
Desorption/Ionization Time-of-Flight Mass Spectrometry (SELDI-TOF MS) and Liquid 
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Chromatography Tandem Mass Spectrometry (LC/MS-MS). In their review, 
Macdougall et al., (2010) discussed the different methodologies available for Hepcidin 
testing including the ELISA technique. In the same review a number of studies done 
on Hepcidin using the ELISA technique were discussed. They noted that Koliaraki and 
colleagues as well as Ganz and colleagues’ work on ELISA conferred that there is no 
cross reactivity between the hepcidin isoforms when using the ELISA technique 
Koliaraki et al.,   2008 in Macdougall et al., (2010); Ganz et al., 2008 in Macdougall 
et al., (2010). It is also important to highlight that the Hepcidin kits used for this study 
noted that there is no significant cross reactivity between hepcidin25 and the other 
isoforms (Cusiobio® n.d.). This feature is important because the work on this research 
aimed at characterising the dynamics of hepcidin 25, excluding other isomers, in 
relation to other variables as described. 
 
An ELISA based immunoassay was chosen because its performance is comparable 
to other technologies. It is also relatively cheap in comparison to technologies such as 
Radioimmunoassay (RIA) and mass spectrometry (MS). These two attributes make an 
ELISA the right choice for an assay in the setting in which Hepcidin testing is being 
proposed. The proposed setting is the testing of Hepcidin in patients with IDA in a 
developing country where health economies are already scanty and stretched. A 
simple ELISA based assay provides a solution as it does not require huge capital 
investments on equipment for the implementation of this assay. The ELISA only 
requires a reader and an incubator as opposed to mass spectrometry which requires 
a mass spectrometer that is more expensive than a reader and incubator combined  
 
3.2.3.5. Serum iron colorimetric assay. 
 
The serum iron assay used in the experiments is based on the measurement of the 
intensity of the colour that forms when ferrous ions (Fe2+) react with FerroZine. The 
assay is sometimes called the Ferrozine method, deriving its name from the ferroin 
compounds that are used. Ferrozine is a chemical compound that forms a stable 
c o l o u r e d  c o m p o u n d   when  it  is  complexed  with  ferrous  ions  (Fe2+) 
(PubChem 2016).  The complex so formed has an absorption peak at 562nm thus the 
absorbances for serum iron determination using this method were carried out at 
562nm. The ferrous ions are liberated from iron complexes and subsequently reduced 
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from ferric (Fe3+) to ferrous state (Fe2+) by a weak acid (CHRONOLAB n.d.) In this 
assay ascorbic acid was used as the weak acid and this was supplied as reagent 2 
(R2) in the kit. The information on the other reagents contained in the iron kit is shown 
in the kit insert in Appendix 1. 
 
The reaction between ferrous ions and FerroZine results in the formation of a coloured 
complex. The intensity of the colour so formed is proportional to the concentration of 
iron in the sample. The colour intensity was measured by a spectrophotometer at a 
wavelength on 562 nanometres (nm).  By using a standard with known concentrations 
of iron the beer lambert’s law could be applied to calculate the concentration of 
iron in the participants’ samples. This assay was performed manually and required the 
use of a spectrophotometer. 
 
3.2.4. Laboratory methods 
 
Full blood count, serum iron and Hepcidin assays were performed on the blood 
samples that were collected in EDTA and SST tubes respectively. All three tests were 
performed in the laboratory in Namibia. Tests for full blood count were performed on 
the day of sample collection while assays for Hepcidin and serum iron were performed 
at a later date. Samples for the latter were kept frozen until the assays were ready to 
be put up. 
 
3.2.4.1.Full blood Count Analysis. 
 
The full blood count tests were performed using a Pentra XL 80 full blood count 
analyser and were analysed on the day of sample collection. The Pentra XL80 is a 
5-part differential analyser which can perform a full blood count and differentiate white 
blood cells. The white blood cells can be differentiated into neutrophils, lymphocytes, 
monocytes, basophils, eosinophils. The white cell differential can be extended to 
include atypical lymphocytes (ALY) and large immature cells (LIC) but these 
parameters are currently for research use only. This analyser uses electrical 
impedance as a principle for the detection and quantitation of red blood cells and 





The principle of electrical impedance is based on the concept of differences in electrical 
resistivity between different cellular components of blood as well as plasma which is 
the acellular element of anticoagulated blood. The architecture or morphological 
differences between the cells determine the level of resistivity and these differences 
can be used to differentiate the types of cells.  A sample of blood is  mixed  with  a  
diluent  solution  which  conducts electricity and  the mixture  is passed through an 
aperture with an electrical current. The aperture diameter for the ABX XL80 analyser 
is 50µm large (ABX user manual n.d.). As the blood mixture passes through the 
aperture, cells offer more resistance than plasma and they generate peaks which are 
then enumerated to give the number of cells. These are then computed by the 
analyser and expressed as number of red blood cells/µL. 
 
The principle used for haemoglobin, spectrophotometry, is different from that for red 
blood cell counting.  Spectrophotometry for Hb determination is based on the 
measurement of absorbance of RBC ABX lyse mixture (ABX Technical manual 
2002).The lyse reagent contains potassium cyanide at 0.03%, ammonium salt and 
phosphate buffered saline (ABX Technical manual 2002). The lyse reagent lyses red 
blood cells and they release haemoglobin which then combines with the potassium 
cyanide to form cyan methaemoglobin. The absorbance of the cyan methaemoglobin 
compound  is then measured  at a wavelength  of  550nm (ABX Technical manual 
2002). The absorbance is converted using beer lambert’s law which states that the 
absorbance of a compound is proportional to its concentration (Swinehart 1962). 
 
3.2.4.2. Serum iron assay 
 
The serum iron assay was performed on all samples from participants meeting the 
inclusion criteria for normal adults as defined by the NaMBTS donation protocol. The 
serum iron levels were measured using a colorimetric assay the principle of which has 
been described in section 3.2.3.4 above. A working reagent was prepared by 
dissolving ascorbic acid in an acetate buffer of pH 4.9 according to the 
manufacturer’s instructions which are attached as Appendix 1. The solution was 
mixed until all the contents were dissolved, and this was labelled as the working 
reagent (WR). 1000μL of the working reagent was pipetted into all the cuvettes followed 
by 3 drops of the FerroZine reagent. The FerroZine reagent was placed in all cuvettes 
except the sample blank cuvette. Before incubating at 37oC for 5 minutes, 200μL of 
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the standard, distilled water and samples were put into the  standard, blank and 
samples cuvettes respectively. 
 
The solutions were incubated for 5 minutes and the optical densities (OD) of the 
mixtures were measured using a spectrophotometer. This was done at 562nm. An 
absorbance  of  the  blank  solution was  also  taken  at the same wavelength  of 
562nm. This was subtracted from the sample absorbance and the concentration of iron 
was calculated as follows: 
 
Iron (μg/dL)= OD Sample-OD blank/OD Standard x100 (concentration of the standard). 
The results were expressed in μg/dL but a conversion factor of 0.179 could be used to 
convert the units for serum iron from μg/dL to μmol/L. 
 
3.2.4.3. Hepcidin assay 
 
The samples for Hepcidin assaying were tested in duplicate using the Hepcidin ELISA 
kits supplied by CUSIBIO®. Anti Hepcidin antibody pre-coated wells were supplied in 
the kit. The wells came in strips with twelve wells on each strip. One hundred 
microlitres (100µl) of prepared standards and samples were added into the wells 
and incubated for 2 hours at 37oC. At the end of the incubation period the liquid 
contents of the wells were decanted. 100µl of biotin labelled antibody was added to 
each well and the mixture incubated for 1 hour at 37oC. After which the liquid from 
each well was removed by aspiration. The wells were washed 3 times using the wash 
solution provided by the kit manufacturer. Subsequently, 100µl of avidin conjugated to 
horse radish peroxidase (HRP) was added to each well and incubates for 1 hour at 
37oC. At the end of the incubation period the HRP-avidin mixture  was  aspirated  before  
the  wells  were  washed  5  times  with  the  wash solution. 90µl of the 
Tetramethylbenzidine (TMB), a peroxidase substrate was added in the wells and 
incubated for 30minutes at 37oC. 
 
The plates were protected from light to avoid it interfering with the colour development. 
The colour reaction was stopped by the addition of 50µl of stop solution before reading 
the optical densities for each well at 450nm. The optical density was read using the 
Biotek ELx800 microtiter plate reader, an automated plate reader from BioTek®.   In 
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each plate all the seven standards   and a blank were  present  in  duplicate.  The  
standards  had  the  following  Hepcidin concentrations   according   to   the   kit   
manufacturer’s   instructions:   300ng/ml; 150ng/ml; 75ng/ml; 37.5ng/ml; 18.75ng/ml; 
9.375ng/ml; 4.6875ng/ml. The logarithmic values of these concentrations were plotted 
against the logarithms of the optical densities obtained and this was the standard 
curve used to calculate sample  results.  The  initial  results  obtained  from  the  
standard  curve  were logarithms of the sample hepcidin concentrations. The anti-




3.3 Quantitative behaviour of Hepcidin in IDA pre- and post- iron treatment 
 
Assessment of Hepcidin values in anaemia helps to elucidate the utility of this analyte 
in the diagnosis and prognosis of iron deficiency anaemia. In this study samples  of  
participants  with  iron  deficiency  anaemia  were  used  to  assess Hepcidin values 
and its characteristics. This was done by measuring the values of Hepcidin, serum iron 
and full blood count parameters such as haemoglobin. The same participants were 
then followed up for subsequent samples to assess the effect of iron administration 
on serum iron and Hepcidin levels as well as full blood count parameters. Results from 
the reference normal range group were also combined with work from the iron 
deficiency anaemia group in order to fully investigate the quantitative behaviour of 
Hepcidin. 
 
Statistical models such as multiple regression and correlation analysis were used to 
assess the value of Hepcidin in comparison to other parameters such as serum iron. 
This was performed on data obtained from both normal healthy participants as well 
as iron deficient group. The inclusion of data obtained from normal healthy adults as 
well as iron deficient participants makes it possible to assess how well Hepcidin is able 
to differentiate between health and disease states. 
 
Hepcidin values are generally reduced in iron deficient states (Young 2009) to 
allow for compensatory increase in iron bioavailability. As already elucidated by 
Nemeth et al., (2004), hepcidin directly controls iron regulation by influencing the 
activity of ferroportin, the only known iron intracellular exporter. Given its direct role 
59 
 
in iron regulation, Hepcidin could therefore be used as a diagnostic indicator or even 
more so a prognostic indicator for disorders associated with iron metabolism. Hepcidin 
values are reduced in iron deplete states in order to facilitate iron loading. A reduction 
in Hepcidin allows for increased availability of ferroportin, an  important  player  in  
transmembrane  iron  transport.  Indeed  Pasricha  et  al., (2014) has demonstrated 
that depressed hepcidin levels are a good indicator of increased iron uptake. The 
reduction in hepcidin values can however be masked by the presence of other 
inflammatory conditions such as infections and malignancies. This drawback is not 
unique to hepcidin alone, current markers of iron dysregulation such as ferritin levels 
are also affected by inflammation (Hoffbrand and Moss 2011). This drawback should 
therefore not be discouraging in the quest for better diagnostic strategies for iron 
deficiency anaemia. 
 
3.3.1. Characteristics of Hepcidin in relation to haemoglobin values 
 
Hepcidin expression is decreased in anaemia and any other conditions which promote 
increased erythropoietic activity (Nicolas et al., 2002; Pak et al., 2006). Anaemia 
signals for increased erythropoietic activity as a compensatory mechanism for the 
reduced haemoglobin levels. Intravenous or subcutaneous administration of 
erythropoietin also increases erythropoietic activity in an effort to increase the 
haemoglobin levels. In both cases more iron is needed for haemoglobin synthesis 
hence increased iron bioavailability is indicated. Hepcidin is therefore suppressed in 
response to the need for more iron; in fact, Mazur et al’s (2003) studies demonstrated 
that iron levels regulate hepcidin expression albeit in a mouse model. 
 
Anaemia results in decreased tissue oxygenation and increased erythropoietin 
production. This is due to the effect of hypoxia or reduced renal tissue oxygenation 
which enhances erythropoietin gene expression. This will subsequently result in 
increased erythropoiesis with consequent reduction of serum and tissue iron (Pak et 
al., 2006). This myriad of events has a combined and an individual inhibitory effect 
on Hepcidin expression. Nicolas et al., (2002) alluded to the fact that decreased tissue 
oxygenation on its own can supress Hepcidin expression. 
 
The reduction in haemoglobin results in reduced Hepcidin levels and inversely an 
increase in haemoglobin levels upregulates hepcidin expression. These characteristics 
make Hepcidin a potentially good biomarker for conditions where the physiological 
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balance of iron is defective such as in iron deficiency anaemia. 
 
3.3.2. Sampling and sample size calculations in the iron deficiency anaemia 
participants 
 
Donors who were temporarily deferred from donating blood due to low haemoglobin 
levels were recruited to participate in this study. These were otherwise healthy 
individuals in good health apart from the presentation of anaemia. As alluded to in our 
previous research, anaemia is a major cause of deferral among blood donors (Gonzo 
et al., 2016). Given the geographical prevalence data, most anaemia cases in Namibia 
are due to iron deficiency (WHO 2015). It therefore became clear that the blood donor 
population makes for a good population to study Hepcidin characteristics in iron 
deficiency anaemia. 
 
A pre-test/post-test study of Hepcidin, full blood count and serum iron parameters was 
carried out using a cross sectional study design. The design was chosen as it enabled 
the researcher to assess the quantitative behaviour of Hepcidin and other related 
parameters pre- and post-iron treatment. This design may be considered as a 
variation of standard cross-sectional studies because it involved two sets of cross-
sectional data collection on the same sample. 
 
A sample size of 40 participants fulfilling the inclusion criteria was used based on the 
same calculation as for the Hepcidin normal reference range group given that similar 
study designs were used in both occasions. The sample size calculation is discussed 
in earlier in section3.2.1. and in our article (Gonzo et al., 2017). The same sample size 
was recruited for the three groups throughout this research work. The three groups 
were; Hepcidin reference normal range group, pre-iron therapy iron deficiency 
anaemia group and the post iron therapy iron deficiency anaemia group. Samples from 
the Hepcidin reference normal range group were used in laboratory experiments 
carried out in chapter 5 to establish baseline Hepcidin levels in normal heathy 
individuals.   Participants in the iron deficiency  anaemia  group  were  followed  up  
after  iron  therapy  and  the  same sample size was maintained. These participants 
were randomly selected from participants fulfilling the inclusion criteria.   In total 240 
blood samples were collected, two from each participant. The two samples were 
sample with an EDTA anticoagulant for full blood count test and an SST sample 




Data on Hepcidin, serum iron and full blood count results was collected from 
donors who were temporarily deferred because of low haemoglobin levels due to iron 
deficiency. Low haemoglobin was defined as haemoglobin level below 125g/L 
according to the NaMBTS guidelines (MoHSS 2010). Their condition, iron deficiency 
anaemia, was assessed by performing a full blood count and serum iron levels. Full 
blood count results can confirm the presence of anaemia and this was one of the 
inclusion criteria for this participant group. Another inclusion criterion was the 
presence of a low serum iron value in participants with low haemoglobin results. This 
combination of results was used to define iron deficiency anaemia. The temporarily 
deferred donors that were recruited into this study met all the donation criteria except 
the low haemoglobin. This made them good candidates for assessment of hepcidin in 
iron deficiency anaemia because other interfering conditions such as bacterial infection 
were excluded by the blood donation criteria. This criterion has been discussed in detail 
in section 3.2.1. The other inclusion/exclusion criteria for the iron deficiency anaemia 
group are tabulated in Table 3.2. 
 
 
Table 3.2: The inclusion and exclusion criteria for participants enrolled in 
establishing the quantitative behaviour of Hepcidin in the iron deficiency 
participant group.  
 Samples for group 2: Iron deficiency anaemia samples 
Inclusion 
criteria: 
• Samples from donors failing CuSO4 test and have low serum iron. 
 
• Samples from temporarily deferred donors with features suggestive 
of iron deficiency anaemia. 
• Samples from donors who qualify to donate blood except for the low 
Hb. These donors were temporarily deferred and asked to come back 
later. 
• Samples from blood donors agreeing to give a second set of blood 
samples on their follow-up visit with the NaMBTS. 
Exclusion 
criteria: 
• Samples from donors deferred for reasons other than low Hb. 
 
• Samples from therapeutic donors 
 
• Samples from participants who fail to come back for testing after 




The same donors were followed up for a subsequent sample after administration of 
iron to assess the effect of iron supplementation on hepcidin values. The same 
samples were also used to confirm that the intervention of iron has corrected the 
anaemia, a  situation  which  further  confirms  the  presence  of  iron  deficiency 
anaemia in the initial samples. 
 
3.3.3. Data collection and ethical approval 
 
Venous  blood  samples  were  collected  from  consenting  temporarily  deferred donors 
who had failed the haemoglobin test. The haemoglobin test was performed at the 
donation site by the NaMBTS staff. The haemoglobin test performed at NaMBTS was 
a copper sulphate specific gravity test. The principle of the copper sulphate test is 
based on the ability of a drop of free-flowing blood to sink in a copper sulphate solution 
with a specific gravity of 1.053g (Mohan et al., 2016). Blood sample with haemoglobin 
levels above 125g/L would sink and samples with lower haemoglobins would fail to 
sink. The blood was collected from a finger prick using  a  capillary  tube.  After  each  
copper  sulphate  haemoglobin  test  the participants were classified as passing 
(normal haemoglobin) or failing (low haemoglobin)  the  copper  sulphate  test  based  
on  the  behaviour  of  the  blood sample in copper sulphate solution. 
 
The participants who failed this initial CuSO4 screening test were deemed to have low 
haemoglobin. The low haemoglobin results were then confirmed by a full blood count 
test in the laboratory. The full blood count gave a haemoglobin value as well as more 
useful information such as the red cell indices. On the day of initial sample 
collection, the participants were informed of the need to collect a subsequent sample 
after they have undergone iron treatment. Participants consenting to providing the two 
samples were then enrolled into the study. These participants were also informed of 
their option to withdraw consent at any stage should they not wish to continue. 
 
The temporarily deferred donors were counselled by the NaMBTS staff regarding their 
haemoglobin status before they were invited to participate in the study. Two samples 
were collected from each participant, one in EDTA and another in an SST tube. The 
sample collected in EDTA was used to perform a full blood count and 
the clotted sample collected in an SST tube was used for the serum iron and Hepcidin 
assays. The subsequent samples were collected three months after the initial sample 
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and the sample types were identical to the initial ones. Samples were collected 
from prospective blood donors presenting at the blood donation clinic any time before 
midday. The timing of blood collection was necessary to minimise the effect of diurnal 
variation on hepcidin and serum iron levels. This practice was also adopted to ensure 
consistency with blood sample collection procedures performed on the reference 
normal range group. The same tests and analysis were performed for both groups 
therefore the same measures to ensure sample validity were employed.  
 
The application for ethical approval for this study covered both the establishment of 
reference normal ranges for hepcidin reported earlier in the previous chapter and 
the characterisation of Hepcidin in iron deficiency anaemia. The ethical issues were 
identical for both groups; apart from the need to collect subsequent samples in the 
iron deficiency group, therefore the permissions that were sought covered the whole 
study. The permissions were sought and granted from the University of Bath REACH, 
Namibia Blood Transfusion Service and the Ministry of Health and Social Services in 
Namibia. 
 
3.3.4. Laboratory methods 
 
3.3.4.1. Hepcidin assay 
 
The assay for Hepcidin testing was the same for all three experiments in order to 
maintain consistency. The Hepcidin ELISA test from Cusabio was used to assess 
hepcidin 25 (Hepcidin) levels the principle of which is described earlier in the previous 
chapter. On this occasion samples for hepcidin analysis were separated and frozen on 
the day of collection. These samples were kept frozen at -70oC for 
not more than 2 months as per kit manufacturer’s recommendations (CUSABIO® 
n.d.). 
 
On the day of experiments samples were taken from the -70oC freezer and thawed and 
brought to room temperature. Once thawed the samples were spun down at 100g 
for 5 minutes before being used to assay for Hepcidin. The reagents and standards 
were prepared before the assay was put up. Standards were prepared by making 
doubling dilutions of the initial standard preparation. The initial standard preparation 
was made by reconstituting the standard with 1000μl of sample diluent to make a 
64 
 
Hepcidin concentration of 300ng/ml. A two-fold dilution was made from the initial 
standard and this was repeated for a further 5 times to make 7 standard solutions with 
Hepcidin concentrations varying from 300ng/ml to 4.69ng/ml. An additional vial 
containing sample diluent only was also used as a blank. 
 
After all the reagents and standards were prepared, the Hepcidin assay for the pre-
iron IDA group was put up by running both the samples and standards in duplicate on 
a 96 well microtiter plate. These were randomly placed in the wells of the microtiter 
plate and the positions noted on a template. The procedure for running the test was as 




























Figure 3.1: Hepcidin assay method showing step by step procedure for 


















The liquid was removed and 100ul of biotin antibody added for a further 1 hour 
 





The plate was washed for 3 times with the wash solution before 100μl of 
 










The TMB mixture was incubated for 30 minutes before a stop solution was 
 





The optical densities of the final solution was determined by measuring 
 






After carrying out the experiments for Hepcidin determinations as described in Figure 
3.1  above  the  optical  density  readings  were  used  to  extrapolate  the Hepcidin 
concentration results from the standard curve. The standard curve was constructed 






3.3.4.2. Full blood count analysis 
 
Samples for full blood count analysis were tested on the day of collection using the 
Pentra XL80 five-part differential analyser. However, the analyser has a 48-hour post 
draw stability which allows it to produce valid results from a sample up to 2 days old 
(ABX user manual n.d). 
 
The principles of measurement for this analyser are discussed earlier in the previous 
chapter. On the day of sample collection, the samples were collected from qualifying 
participants and placed in a temperature controlled environment. Samples were stored 
at 4-8oC before processing. They were then transported to the National University of 
Science and Technology (NUST) for processing. During processing 53μL of properly 
mixed whole blood was aspirated into the analyser. The whole blood was obtained 
from samples collected in EDTA specifically to assess full blood count parameters for 
the Hepcidin study. 
 
In the FBC analyser the aspirated blood was split into different counting/analysis 
chambers utilising the multi-distribution sampling system (MDSS) technological 
capability of the analyser (ABX technical manual 2002). A full range of results 
were generated from the respective counting/ analysis chambers. FBC parameters 
produced include haemoglobin, MCV, MCH, MCHC, platelets and RDW of which some 
of them where recorded on the data collection tool. The FBC results were obtained for 
both the pre- iron and post- iron groups. 
 
3.3.4.3. Serum iron assays 
 
Serum iron results were obtained using the FerroZine colourimetry method for 
quantitative determination of iron. The assays were performed in batches using serum 
that was collected and stored at -70oC. According to the manufacturer’s instructions as 
indicated in appendix 1, samples could be stored for a week in a refrigerator at 2-8oC 
(CHRONOLAB n.d.). In this case the samples were however frozen which allowed 
them to be stable for longer durations. In this study the samples were frozen and stored 
for at most 6 weeks before being assayed. 
 
The principle of the FerroZine calorimetric method for determination of serum iron is 
described earlier in the previous chapter. Samples collected from deferred anaemic 
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blood donors were assayed for serum iron to confirm the presence of iron deficiency. 
The same group of participants were followed up after administration of iron therapy, 
mainly oral iron tablets, and another set of samples collected. The second set of 
samples was assayed for serum iron to assess the effect of previously administered 
iron therapy. The procedure for performing the serum iron test is as described earlier 
in the previous chapter. 
 
3.4. Data management   
 
Data collected in the form of participant details was anonymised by the use of unique 
identification numbers. Other forms of data collected were results from the laboratory 
experiments. The results included haemoglobin (Hb) levels, Hepcidin values as well as 
serum iron levels. These results were collected from both the reference normal range 
group and the iron deficiency anaemia group. The results were collected using a data 
collection tool which captured all the raw data. Original readings from the ELISA plate 
reader were printed on a template and where the sample numbers were also captured. 
This was transferred to an excel spreadsheet which was used as the secondary data 
collection tool. The data was then entered into a statistical software for cleaning and 
analysis. 
 
The data generated from the two studies was analysed using statistical package for 
the social sciences (SPSS) version 24. Both the data analysis and cleaning was 
performed using SPSS. Data cleaning was performed by paying attention to data 
cleaning items such as participant identification numbers, missing values, skip patterns 
as well as implausible values for the analytes that were tested.  
 
The participant identification numbers were put in a frequency table to check if there 
were any duplicate entries. Missing values are usually given a code in SPSS. This 
however was not done for the data generated in both the reference normal range and 
the iron deficiency group. Missing data in SPSS was investigated by going back to the 
original data set to confirm if the values were not erroneously omitted. Once confirmed 
that the values are genuinely missing the default series mean method was employed 
to replace the missing values. With this method, the mean value of the analyte in 
question was calculated and the value was used to replace the missing data in that 
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series.  The same approach was also used with implausible values after accounting for 
the quality of samples. Sample validity and sample integrity is paramount to generating 
useable data therefore the quality of samples was assessed before and after 
performing the experiments to generate data. 
 
3.4.1. Assessment of normality 
 
The distribution of the generated data was assessed in two ways by visually inspecting 
the histograms generated and also by statistically analysing descriptive statistics in 
SPSS. Visual inspection has the advantage of making judgement based on the 
graphical interpretation of the histograms or any other such graphical presentations. 
Furthermore, visual inspection enables a good judgement to be made where statistical 
tests prove to be over sensitive or even under sensitive. Visual assessment however 
is more reliable with experienced individuals thus both approaches were used in this 
project.  
 
Statistical analysis of descriptive statistics was performed using the ‘explore’ command 
in SPSS. In instances where the data failed the normality test data transformation was 
performed and tested for normality again. Common transformations include converting 
variables to their logarithmic values or using square roots of the dependent variables. 
 
3.4.2. Power calculation 
 
A power calculation was performed to ensure a sufficient sample size was determined 
by the sample size calculation. In calculating the desired power, the standardised 
difference (Sdiff) was obtained using the following formular. 
 
Sdiff= Difference between means 
  Population standard deviation (Jones et al., 2003). 
 
The minimum desired power was set at 0.80 and the sample size was extrapolated 
from the Altman’s nomogram for sample calculation using power and standardised 





The difference between means was obtained by subtracting mean Hepcidin 
concentrations of health non-IDA participants as obtained from Sdgou et al., (2015), 
Gonzo et al., (2017) and Pasricha et al., (2011) from the mean Hepcidin concentrations 
of participants with IDA.  
 
Means for IDA participants were obtained from a study by Takasawa et al., (2015) and 
this current study. The means are tabulated in Table 3.1 below. 
 
Table 3.3: Mean Hepcidin concentrations obtained from other studies. 
Hepcidin means from non-IDA participants Hepcidin means from IDA participants 
Source Hepcidin (ng/mL) Source Hepcidin (ng/mL) 
Sdgou et al., (2015) 45.60; 61.27; 
47.58; 51.39; 
55.38; 60.84 
Takasawa et al., (2015) 10.8 
Gonzo et al., (2017) 51.99 Current study 9.85 
Pasricha et al., (2011) 28.5   
Average 50.32  10.33 
 
The population standard deviation (SD) of 18.94ng/mL was used. This was obtained 
from previous work carried out on Hepcidin by Sdgou et al., (2015), Parischa et al ., 
(2011) and Galesloot et al ., (2011).  
 
A standardised difference of >1.2 was obtained. Extrapolating from the nomogram, a 
sample size of 40 participants would give a power of >0.95 which was above the set 



























Results were obtained from the Reference Normal Range (RNR) group and the Iron 
Deficiency Anaemia (IDA) group. Data from the reference normal range group was 
used to establish Hepcidin normal values within the Namibian populace. Furthermore, 
data from the iron deficient group was used to study the quantitative behaviour of 
Hepcidin in both normal and inadequate iron states. 
 
In both study populations, incomplete results were excluded from the study. Incomplete 
results were mainly due to the presence of data sets where either one or more results 
were missing for a particular blood sample. Another reason for missing data was the 
inability to obtain further samples from the participants. One sample in the reference 
normal range group had full blood count results but could not be tested for serum iron 
and Hepcidin. The blood sample was found to be haemolysed after thawing. 
Haemolysis interferes with spectrophotometric measurement of iron and Hepcidin 
therefore a complete data set could not be obtained, and this resulted in the blood 
sample being excluded. 
 
In the IDA study population there was a notable degree of sample attrition as 
participants failed to turn up for subsequent blood sample collections. Due to the 
nature of the sampling method; sequential sampling, follow up samples were collected 
3 months after the initial blood sample collection. As a result of no-shows, a further 5 
participants were recruited to account for sample attrition as some participants did not 
turn up for follow up samples after initiating iron treatment. Recruitment of additional 
participants allowed for the collection of data from a complete set of samples as 






4.1:  Results from the Reference Normal Range (RNR) group 
 
4.1.1 Demographic features 
 
A total of 40 donors were recruited to participate using a multistage sampling method 
which comprised simple random sampling and stratified sampling. Donors were 
stratified according to whether they were eligible to donate on the day they presented 
at the blood transfusion service for donation. Those able to donate were randomly 
selected and recruited into the study between October 2015 and June 2016. Thirty-
nine (39) samples from the recruited participants were tested. The other blood sample 
could not be tested due to sample validity issues. Age, serum iron and some 
haematological values of the tested parameters are summarised in Table 4.1 
 
Table 4.1: Hepcidin, serum iron levels and haematological values in the 
reference normal population group 
   
Variable Average Standard deviation 
(SD) 
Age (years) 40 years 10.511 
Haemoglobin 143.56g/L 12.92 
Mean corpuscular volume 92.53 FL 4.93 
Hepcidin 51.99ng/ml 17.44 
Serum iron 91.32μg/dL 16.78 
 
Serum iron values for this sample ranged from 69μg/dL to 150μg/dL with a median 
value of 91.5μg/dL. The mean value for serum iron (91.32μg/dL) gives a good 
indication of iron bioavailability. 
 
The mean Hepcidin concentration for the whole study population was 51.99ng/ml. 
Thirty-n ine (39)  samples  were  tested  with  19  females  and  20  males.  The 
haemoglobin values ranged from 1126g/L to168g/L for males and 125g/L to 157g/L 
for females all of which were normal for both genders. Compared to the 
haemoglobin values, the Hepcidin values were much spread out.  
These are illustrated in Figure 4.1 below which shows the distribution of Hepcidin 




Figure 4.1: Values and distribution of Hepcidin levels in the reference 













Figure 4.1 indicates that the lowest and highest hepcidin values in the reference 
normal range group. Most of the values were above 40ng/ml with 9 (~25%) of them 
having Hepcidin values of at least 70ng/mL. 
 
4.1.2. Data analysis 
 
Data analysis for this participant group was performed to obtain Hepcidin reference 
normal ranges within this study group. Confidence intervals and reference ranges 
were calculated using the following function as adopted from Altman (1991). 
 
Formula for reference ranges calculation: Altman 1991; pp.421-422. 
This was performed using the following: 
X bar= normal range 
 
N= sample size 
 
S= sample standard deviation 
 
Se= se is the standard error of the reference range limits ci 
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= confidence interval for the reference range limits 
z = a quantile from the standard normal distribution and 
 
c = % range coverage/100 (in this case 0.95 for a 95% reference range). 
 
The reference normal range for Hepcidin in this study was 17.80-86.18ng/mL for the 
entire study population at 95% which is within 2SDs. The reference range of normal 
at 99% was 34.55-69.43ng/ml which is within 1SD. For the work on IDA a reference 
range within 2SD was adopted as the normal reference range for Hepcidin in the 
population under study. For the two genders, the ranges for the females were 
17.19-91.24ng/mL and for males it was 18.23-81.54ng/mL both at 95%. Other 
statistical values are indicated in Table 4.2 below. 
 
Table 4.2: Statistical values for Hepcidin and haemoglobin in the reference 








 Non-gender specific Female Male Female Male 
Mean 51.99 14.36 54.21 49.89 13.83 14.86 
Median 50.02 14.10 51.51 49.02 13.70 14.45 
Mode 32.67 14.10 75.83 N/A 13.70 14.10 
Standard Deviation 17.44 1.28 18.89 16.15 0.91 1.39 
Minimum 26.91 12.50 26.91 28.89 12.50 12.60 
Maximum 87.90 16.80 81.97 87.90 15.70 16.80 
95% Lower Limit 17.80 11.86 17.19 18.23 12.04 12.14 
95% Upper Limit 86.18 16.86 91.24 81.54 15.61 17.58 



























The results in Table 4.2 above show lower confidence levels (LCL) and upper 
confidence levels (UCL) for both the lower and upper limits. The standard deviation 
of Hepcidin for females (18.89) was higher than that obtained for males (16.15) 





4.2 Results for the Iron Deficiency Anaemia (IDA) group:  
 
A total of forty participants were required for the study but forty-five  prospective  
donors were recruited to compensate  for those who dropped out of the study. The 
participants were prospective donors who failed the  haemoglobin  CuSO4  test. They 
were recruited into the study to assess the quantitative behaviour of Hepcidin in 
anaemia. This was done by testing the participants’ blood samples for full blood count, 
serum iron and Hepcidin levels. These participants were followed up after iron 
treatment and tested for the same parameters.   
 
Results in this section are presented in three sub sections namely: 
• results from participants with iron deficiency anaemia before iron therapy, 
• results from the same participant group after iron therapy and  
• a comparison of the two groups.  
Where possible, results from the normal healthy participants group were also 
combined with ones from the iron deficiency anaemia group. This was done to obtain 
a full picture of the characteristics of the analytes being investigated. The comparison 
mainly focused on the analytes of interest such as the similarities or differences of 
Hepcidin, serum iron and full blood count parameters. The full blood count 
parameters w h i c h  w e r e  looked at included haemoglobin (Hb), red cell distribution 
width (RDWcv) and the red cell indices such as mean corpuscular volume (MCV) and 
mean corpuscular haemoglobin concentration (MCHC). 
 
4.2.1. Results before treatment with iron 
 
Serum iron levels were measured in the IDA group and it was noted that the majority 
of participants in this group were iron deficient. The histogram in Figure 4.2 below 










Figure 4.2: Histogram of serum iron levels in the IDA participant group before 
treatment with iron supplementation. 
 
 
Figure 4.3 below, shows the same serum iron levels in relation to Hepcidin and 
haemoglobin values in the iron deficiency anaemia group. These values were obtained 
before participants commenced treatment with iron in order to have a clear 











Figure 4.3: Graph showing iron, Hepcidin and haemoglobin values in the iron 
deficiency anaemia group 
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.From the chart in figure 4.3 above it can be noted that the serum iron level values 
ranged from 6.99μg/dL to 56.09μg/dL in this study group. The haemoglobin and 
Hepcidin values ranged from 80g/L to 125g/L and 0.10ng/mL  to  39.40ng/mL  
respectively  in  the  same  study  group. These values confirm the presence of iron 
deficiency anaemia with some level of certainty given low haemoglobin values in the 
presence of suppressed serum iron and Hepcidin levels. 
 
4.2.1.1. The effect of iron and the effect of Hepcidin on Haemoglobin 
 
A correlation analysis was performed to evaluate the strength of relationships between 
serum iron, Hepcidin and haemoglobin. These relationships were assessed in the 
presence of inadequate bioavailable iron and the results are tabulated in Table 4.3 
below. 
Table 4.3: Individual effects of serum iron (a) and Hepcidin (b) on Hb: An analysis 







Serum iron Log serum iron Hepcidin Log Hepcidin 
0.10 0.03 0.26 0.37  
0.01 0.01 0.07 0.13 
40 40 40 40 
 





The correlation analysis above shows the associations between serum iron, Hepcidin 
and haemoglobin levels. Correlation analysis and multiple regression are different, but 
they complement each other. Correlation analysis describes the linear relationship 
between two variables, it focuses on the strength of the relationships. It is pertinent to 
note that correlation and causation are different. Regression analysis can predict the 
relationships between two variables, it can show how one variable changes with the 
other. Furthermore, multiple regression can be used to predict how one dependent 
variable changes in line with other independent variables. To compliment the correlation 
analysis results above, outputs from a multiple regression analysis are presented 
below.  Table 4.4 shows a summary  of  the  values  obtained  after  performing multiple 
regression analysis between haemoglobin and other variables. The independent 
variables investigated were Hepcidin, serum iron, red cell indices and red cell count. 
 
Table 4.4: Multiple regression analysis showing the effect of various factors on 
haemoglobin 
Multiple R 77.05% 
R-Square 59.36% 
R-Square Adjusted 54.64% 
S (Root Mean Square Error) 1.48 
 
From the multiple regression Table 4.4 above, it can be noted that the r overall 
(highlighted in red) is 0.7705 which is reasonably close to 1. The r overall, usually 
termed multiple R shows the combined effect of the named variables to haemoglobin. 
The eight independent variables were RBC, Hct, MCV, MCH, MCHC, serum iron, 
Hepcidin and RDWcv. The obtained value of 77.05% show that all the eight variables 
combined have a reasonable effect towards the variability of haemoglobin. This 
indicates that experimental results from this study looked at most of the significant 
players in anaemia. This also helps to explain the low haemoglobin correlation 
values with the two variables; serum iron and hepcidin as seen in Tables 4.3a and 








4.2.1.2. The effects of various factors on Hepcidin 
 
Having looked at how haemoglobin is associated with other haematological 
parameters that are relevant to iron deficiency anaemia in Table 4.4, it is also important 
to describe the behaviour of Hepcidin in relation to the full blood count parameters. 
Table 4.5 below shows the correlation values of Hepcidin with red cell indices and 
serum iron. The correlations were performed on data obtained from both the IDA 
and the normal healthy adult participant groups. 
 
Table 4.5: Effect of various parameters on Hepcidin, a correlational analysis 
  Hb RBC HCT MCV MCH MCHC RDWcv Iron Hepcidin 
Hb 1         
RBC 0.77 1        
HCT 0.94 0.84 1       
MCV 0.53 0.02 0.55 1      
MCH 0.44 -0.15 0.35 0.87 1     
MCHC -0.25 -0.19 -0.31 -0.26 -0.09 1    
RDWcv -0.22 -0.23 -0.18 0.04 -0.02 -0.07 1   
Iron 0.74 0.58 0.78 0.52 0.41 -0.27 -0.16 1  
Hepcidin 0.62 0.46 0.65 0.48 0.36 -0.21 -0.08 0.71 1 
 
 
Table 4.5 shows the association of Hepcidin with other parameters, highlighted in 
yellow.  In that row it can be seen that iron has the highest correlation value 
(r=0.71) with Hepcidin followed by haematocrit (HCT) (r=0.65) and then haemoglobin 
(r= 0.62) compared to all the other parameters. The iron-Hepcidin correlation can be 
regarded as strong implying that there is a strong positive association between iron 
and Hepcidin. This confirms that the behaviour of Hepcidin is positively influenced by 
iron in situations where iron deficiency is not present as  well  as  where  there  is  
not  enough  iron  available  for  normal physiological functions. It therefore 





Full blood count parameters (Hb, RBC, Hct, MCHC and RDWcv) t h a t  a r e  
highlighted in blue on Table 4 . 5  have moderate to very strong positive 
associations with each other. These are RBC and Hb (r=0.77); RBC and Hct (r= 0.84) 
and Hb and Hct (r= 0.94).  The serum iron levels also have strong correlations with Hb, 
RBC, HCT and MCV. These are highlighted in green on Table 4.5 above.  
It is interesting to note that MCHC and RDWcv have negative correlations with almost 
all the parameters. The associations are however weak (r > -0.25). 
 
Full blood count parameters, in particular haemoglobin levels remain the hallmark for 
defining anaemia as such these results are important in diagnosis of iron deficiency 
anaemia. It is suggested that the full blood count parameters are not replaced but 
are complemented with Hepcidin testing. Other parameters which are currently in 
routine use to assess iron bioavailability could benefit from the introduction of 
Hepcidin testing because of Hepcidin’s response. To illustrate this further, an excerpt 
from the m u l t i p l e  regression analysis output is shown in Table 4.6. 
 
Table 4 . 6 : Regression analysis data showing the effects of various factors 
on Hepcidin 
Multiple R 55.40% 
R-Square 30.70% 
R-Square Adjusted 12.80% 
S (Root Mean Square Error) 3.15 
Parameter Coefficients P-value 
Hb 5.19 0.91 
RBC 34.55 0.46 
HCT -5.14 0.76 
MCV 7.35 0.33 
MCH -17.60 0.35 
MCHC 14.70 0.26 
RDWcv 0.51 0.52 
Iron 0.34 0.01 
 
From Table 4.6, it can be seen that the r overall (multiple R) of 0.554 demonstrates a 
fair effect of the combined eight variables on Hepcidin. The R2   value, also known as 
the coefficient of multiple determination, shows that the eight factors combined 




From the coefficients values in Table 4.6 above, it means that for every 1x1012 cells/L 
increase in red blood cells (RBC) Hepcidin will increase by 34.55ng/mL while holding 
the remaining parameters constant. Equally for every 1g/dL increase in haemoglobin 
Hepcidin will increase by 5.19ng/mL if we hold the remaining parameters constant. 
These are reasonable effects which however needs further explanation in light of the 
role of iron bioavailability in red cell formation.  In holding other parameters constant 
while increasing the haemoglobin level, it means iron mobilisation from iron stores or 
absorption from the duodenum has to be increased to cater for iron usage in 
haemoglobin production. Hepcidin expression is subsequently upregulated in response 
to the correcting anaemia condition. 
 
The effect of red blood cells and haemoglobin on Hepcidin is however dependant on 
iron because Hepcidin regulates iron and iron is used in the production of 
haemoglobin. The probability values in Table 4.6 above can help to illustrate that. On 
all the parameters, only iron has a statistically significant effect on Hepcidin (p= 
0.01), the rest are not close to 0. 
 
The  average  haemoglobin  level  in  this  study  group  was 11.60g/dL with a mode 
of 12.30g/dL of which both figures indicate reduced haemoglobin  levels.  Since  these  
are  two  of  the  three  measures  of  central tendency we can associate the presence 
of anaemia in this study group given the low values of the mean and the mode. To 















Table 4.7: Descriptive statistics values for the pre-iron therapy 
group 
Pre-iron group Hb (g/dL) Iron (ug/dL) Hepcidin (mg/mL) Log Hepcidin Log Iron 
Mean 11.6 24.437 9.848 0.673 1.323 
Standard Error 0.128 2.081 1.684 0.101 0.039 
Median 11.8 22.387 5.834 0.766 1.350 
Mode 12.3 14.657 N/A N/A 1.166 
S D 0.808 13.159 10.650 0.636 0.249 
Variance 0.653 173.166 113.425 0.404 0.062 
Range 4.5 49.103 39.301 2.617 0.905 
Minimum 8.0 6.988 0.095 -1.022 0.844 
Maximum 12.5 56.092 39.396 1.595 1.749 
Count 40 40 40 40 40 
C. I (95.0%) +/- 0.258 +/- 4.209 +/- 3.406 +/- 0.203 +/- 0.080 
 
4.2.2. Results of the IDA group after treatment with iron. 
 
The same group of iron deficiency anaemia participants as discussed in section 
4.2.1 underwent treatment with iron before being tested again at 3 months. The 
mean values for the relevant parameters were obtained from respective paired t- tests 
and are shown in Table 4.8. 
 
Table 4 . 8 : Comparison of Haemoglobin, Hepcidin and iron values pre- a n d  




Post iron treatment p-value from the 
respective paired 
t-test 
Average (SD) Average (SD) 














9.848 (+/- 10.65) 
 







24.44 (+/- 13.16) 
 





The average haemoglobin levels were much higher after treatment with iron, an 
indication that administration of iron had a positive effect on the haematological 
state of the participants. Hepcidin mean also went up together with serum iron values 
signalling an increase in iron bioavailability. To assess the utility of Hepcidin as a 
diagnostic test in assessing iron bioavailability a ROC analysis was performed. Table 
4.9 below shows sensitivity and specificity calculations done for the Hepcidin test. 
The values of the predictions are also included in the tables together with the formulae 
used to calculate them. 
 




















91.19% to 100.00% 
 
 



























38.60% to 61.40% 
 






89.72% to 100.00% 
 




86.96 % (*) 
 
73.74% to 95.06% 
 
The favourable results shown in Table 4.9 above show that Hepcidin is a potentially 
useful diagnostic test. The correlation analysis on the post iron treatment group would 
also help to ascertain the utility of routine Hepcidin testing in iron deficiency anaemia 




Table 4 . 1 0 : Serum iron, Hepcidin and haemoglobin correlation analysis 













Post Hb 1 0.01 0.02 0.11 0.15 
Post iron  1 1.00 0.22 0.27 
Log Post iron   1 0.22 0.27 
Post Hepcidin    1 0.94 




The two analytes, serum iron and Hepcidin have very weak correlations with 
haemoglobin levels as shown by the highlighted r values in the correlation matrix in 
Table 4.10. Hepcidin nevertheless has a better correlation than iron. The use of 
logarithmic values of Hepcidin tends to give better results. To demonstrate this 
further, scatter plots showing the different correlations with haemoglobin values 
after treatment with iron are shown in Figure 4.4 below. The four scatter plots indicate 
the relationships between haemoglobin (HB) & iron and haemoglobin & Hepcidin 
(HEP). The figure also shows the relationship between haemoglobin and logarithmic 
























From the scatterplots in Figure 4.4 above it can be shown that log Hepcidin values 
offer a better relationship with haemoglobin in the IDA participants who had undergone 
treatment with iron. The trend lines for serum iron values are almost horizontal. 
Compared to the Hepcidin trend lines, Hepcidin appears to have an association  with  
haemoglobin.  Logarithmic  values  of  Hepcidin  have  a  slightly better positive 
correlation than absolute Hepcidin values. 
 
Generally, the behaviour of Hepcidin in both iron replete and iron deplete states is 
consistent with the anaemic status of the samples under study. The Hepcidin 
levels are depressed in iron deplete states. On the contrary, Hepcidin levels return 
to normal in iron replete states. Its performance however is strongly linked to iron 




























haemoglobin levels were affected by treatment with iron in this participant group.  
Figure 4.5 and 4.6 illustrate this effect. 
 
Figure 4.5: Chart showing the effect of iron treatment on actual serum iron, 












140 Increase in Hb 
(g/L) 
 












In Figure 4.5 above an increase in both haemoglobin and serum iron was noted. 
In most cases the trends in the magnitude of increase are similar for both 
haemoglobin and serum iron illustrating that haemoglobin levels increases 
with iron bioavailability in IDA. The increase in Hepcidin values however is more 
pronounced than serum iron. The percentage increase for Hepcidin is even much 
more pronounced with values above 1000% increase being common. The 
magnitudes of the increases are also shown in Figure 4 . 6  below as percentage 
increases in the three parameters. 
 
Figure 4.6: Chart showing the effect of iron treatment on serum iron, Hepcidin 
and haemoglobin levels as percentage increments. 
 
 
The line chart in Figure 4.5 and the radar chart in Figure 4.6 show that most 
participants responded positively to iron treatment.  
 
The serum iron values increase was much higher than that of haemoglobin in all the 
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however much higher than for both iron and haemoglobin.  The increase in 
haemoglobin ranged from 5.7g/L to 14g/L and serum iron increases were between 
18μg/dL to 91μg/dL. Hepcidin increments where much more pronounced ranging 
from -0.19ng/mL to 229ng/mL. The average percentage increase in iron, 
haemoglobin and Hepcidin was 353.2%, 14.6% and >5000% respectively. On the 
chart in Figure 4.6 the percentage increase of Hepcidin was plotted as a tenth (10-1) 
of the percentage increase to enable it to fit on the same gridlines. This demonstrates 
the vast difference in percentage increments between serum iron and Hepcidin 
levels. 
 
4.2.3. Comparative analysis of pre-and post-iron treatment results 
 
The comparative analysis of pre-and post-iron treatment results in Table 4.11 help 
us to study Hepcidin trends found in the prognosis of iron deficiency anaemia. The   
haemoglobin, iron and Hepcidin values changed as a result of iron treatment given 
to participants. The mean values for haemoglobin, Hepcidin and serum iron in 
Table 4.11 give a general idea of how these parameters changed in the different 
situations. 
 
Table 4.11: Mean values for Hb, Hepcidin and serum iron in different 
participant groups 
 Cut off values Participant group 



















17.80 51.99 9.845 79.85 
 
Log Hepcidin 




58.40 91.30 24.40 80.10 
 
 
The values for the three participant groups were as expected when compared to 
the  cut off  values  for  haemoglobin,  Hepcidin  and  serum  iron.   
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The  pre- iron treatment group had values which were lower than the cut off 
(lower limit of normal) indicating the presence of  iron deficiency anaemia.  The 
haemoglobin levels in the post iron treatment group showed a marked increase 
compared to the pre- i ron  treatment group as reflected by the mean Hb levels 
in Table 4 .11 . The serum iron and Hepcidin mean values also show a similar 
trend with the mean increase of 70.00ng/mL and 55.7μg/dL for Hepcidin and serum 
iron respectively. The increase in the means for serum iron and Hepcidin were 
related  to  the  rise  in  haemoglobin  levels.  It is therefore useful to take a closer 
look at the distribution of the change in haemoglobin levels (Δ Hb) in the studied 
samples by looking at Figure 4.6 in conjunction with Table 4.11 showing the 
correlation data. The correlations in Table 4.12 refer to the pre-and post-iron 
treatment states.  
 
Table 4.12: Correlations between Hepcidin, serum iron, Δ Hepcidin, Δ serum 





















PRE-HB 1         
POST IRON -0.03 1        
PRE-IRON 0.10 -0.10 1       
POST HB 0.74 0.02 0.05 1      
PRE-HEP 0.26 -0.00 0.46 0.24 1     
POST HEP 0.11 0.22 -0.06 0.11 -0.02 1    
delta HEP 0.04 0.21 -0.17 0.05 -0.28 0.97 1   
delta IRON -0.09 0.64 -0.83 -0.03  0.17 0.25 1   -0.36  






















The research was aimed at investigating the behaviour of Hepcidin under different 
experimental conditions. Hepcidin together with other analytes, such as serum iron 
and full blood counts, were assessed in normal adult participants as well as 
participants with iron deficiency anaemia.  The use of different conditions has 
helped in establishing a reference normal range for use in this study and  in 
clarifying the potential usefulness of Hepcidin in iron deficiency anaemia.  
 
5.1. Reference Normal Range group 
 
Hepcidin reference normal ranges are useful as baseline information for the 
elucidation of the properties of this molecule in both iron deficient and iron replete 
states. Establishment of the reference normal ranges made it possible to assess 
the usefulness of hepcidin values in iron deficiency anaemia in this study. The 
reference normal range values established in this study were 17.80ng/mL to 
86.18ng/mL without stratifying for gender. After stratification the reference normal 
range values were 17.19ng/mL to 91.24ng/mL for females and 18.23ng/mL to 
81.54ng/mL for males. The reference normal range participant group provided 
sufficient data that is adequate to allow for this study on Hepcidin in iron deficiency 
anaemia to take place in the adult population.  
 
Hepcidin values in the reference normal range (RNR) group ranged from 
29.80ng/mL to 87.80ng/mL in the entire participant group. As shown in Table 4.1, 
the standard deviation of Hepcidin for females (18.89) was higher than that obtained 
for males (16.15) despite males having more samples than females. This 
demonstrates that the Hepcidin values for males were more concentrated around the 
mean compared to values obtain from female participants. It is important to note that 
for the entire study population the standard deviation of 17.44 obtained for Hepcidin 
in this study is slightly lower but consistent with what was obtained in similar studies 
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(Galesloot et al., 2011; Sdogou et al., 2015) that were used to calculate the sample 
size for this study. 
 
For haemoglobin determinations, the minimum value was 125g/L which indicates 
that no anaemic individuals were recruited in this study group. The range for 
haemoglobin values were from 125.00g/L to 157.00g/L for females and 126.00g/L 
to 168.00g/L for males which is normal for the adult population. The mean, mode 
and median values for haemoglobin were close to each other. These values are 
measures of centrality which might mean the haemoglobin values in the study group 
are close to each other and this is supported by the low standard deviations for 
haemoglobin as indicated in Table 4.2. 
 
The reference normal ranges established for the Namibian blood donor population 
are consistent with those established elsewhere (Parischa et al., 2011; Galesloot 
et al., 2011; Sdogou et al., 2015) albeit in different age groups.  It is therefore 
reasonable to accept these as the true reflection of the Hepcidin levels in the blood 
donor population which in this case was used as a representation of the Namibian 
populace. The range of Hepcidin levels obtained in this study group was 60.99ng/mL 
for the entire study population. From established reference normal ranges elsewhere 
(Sdogou et al., 2015; Galesloot et al., 2011; Parischa et al., 2011) it is apparent 
that there is no suppression of Hepcidin expression in this group. These results 
together with serum iron level values determined in the same group, confirms the 
eligibility of the study group as a genuine group for the establishment on reference 
normal ranges. It is also important to note that the +\- 1SD value  (17.44ng/mL) 
obtained for Hepcidin was slightly lower than what was obtained elsewhere in 
studies by Sdogou et al., (2015).This SD also indicates that the Hepcidin values 
obtained are reasonably spread around the mean. 
 
The serum iron values were obtained in order to confirm the absence of iron 
deficiency in this group of participants. The serum iron levels ranged from 69μg/dL 
to 150μg/dL, results which showed that all the samples used had normal iron 
levels. These results are consistent with reference normal range values which are 
between 40μg/dL-155μg/dL for females and 55μg/dL-160μg/dL for males (Gomella 
and Haist 2007). The modal value for the serum iron levels was 96μg/dL and 
together  with  other  values  obtained,  indicates  good  iron  bioavailability  in  the 
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normal reference range group. Given the effect of iron levels on Hepcidin values, it 
is comforting to note that the Hepcidin reference ranges were derived from a 
population with normal serum iron levels. 
 
The comparability of the study results to reference ranges established elsewhere 
makes it possible for us to use them in this study without incurring prohibitive costs 
associated with establishing comprehensive age and gender stratified reference 
normal ranges. This activity would however be advised when incorporating Hepcidin 
as a routine diagnostic test in practice. Alternatively, laboratories could opt to 
verify reference normal ranges established elsewhere with the intention of adopting 
the same values. Further reference normal range studies in different participant 
groups other than blood donors would also be useful in establishing reference normal 
ranges that can be used nationwide to run an external quality assurance  programme 
(EQAP) for the laboratories. 
 
5.2 Iron Deficiency Anaemia (IDA) group 
 
One of the objectives of this study was to measure Hepcidin levels together with 
other makers of iron deficiency anaemia (IDA) such as Hb, MCV and MCHC in 
patients with IDA. The measured parameters were then compared to those obtained 
in the reference normal range group. The other specific objective was to 
characterise the quantitative behaviour of Hepcidin. This was done by assessing 
the associations of Hepcidin with the obtained parameters in the pre- i ron  IDA 
group and then follow up the same group after iron treatment. In some instances, 
the effect of various parameters on Hepcidin was also assessed using data which 
encompassed values from both the healthy and the iron deficient participant groups. 
 
5.2.1 Haemoglobin, iron and Hepcidin values in iron deficiency anaemia 
 
Figure 4.3 indicate that haemoglobin, serum iron and Hepcidin values were 
consistent with iron deficiency states. The haemoglobin values were below 125g/L 
which is the threshold for defining anaemia at NamBTS  (MoHSS 2012). Full blood 
count parameters, in particular, haemoglobin levels remain the hallmark for defining 
anaemia as such these results are important in diagnosis of iron deficiency anaemia. 
Other parameters such as haemoglobin which are currently in routine use to assess 
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iron bioavailability could benefit from the introduction of Hepcidin testing because 
of Hepcidin’s response. To illustrate this further, an excerpt from the regression 
analysis output shown in Table 4.6 indicated that for every 1g/dL increase in 
haemoglobin, Hepcidin will increase by 5.19ng/mL while holding other parameters 
constant. Such a magnified increase could help amplify small changes in 
haemoglobin levels. 
 
From Table 4.7 it can be noted that the entire mean values for serum iron, 
haemoglobin and Hepcidin are reduced. The median values are also below the 
lower limits of normal and this is expected in iron deficiency anaemia. The mean 
hepcidin levels is almost half t h e  lower limit of normal as determined from the 
reference normal range group. On the other hand, the mean serum iron level is 
reduced by a slightly higher magnitude comparing it to the lower limit of normal 
for serum iron in both genders. 
 
The modal value for serum iron was 14.66μg/dL but there was no mode for 
Hepcidin as all samples yielded unique values. The mean and median values for 
Hepcidin differ moderately. The mean was larger than the median indicating that 
the data is positively skewed. The use of logarithmic values of Hepcidin however 
corrects the skewedness as the mean and median values of log Hepcidin became  
much closer. It may be useful to introduce the use of logarithmic values of Hepcidin 
in place of the absolute Hepcidin values because the log values correct for 
skewedness. 
 
A closer look at the graph in Figure 4.3 shows some relationship between Hepcidin, 
serum iron and haemoglobin levels. The haemoglobin levels are mostly around 
10g/dL (100g/L) and their levels are between those for serum iron and Hepcidin in 
most cases. There are however instances where the haemoglobin values are higher 
than serum iron levels. These comparisons were made on values obtained when 
using conventional units of measurement commonly reported in routine medical 
diagnostic laboratories. Serum iron levels show the highest peaks with most of them 
above 20μg/dL but below 60μg/dL. All the serum iron values are below the lower 
limit of normal for a healthy adult which is 58.4µg/dL. This further confirms that 
the participants recruited into this study had low iron levels. The results that followed 





From the results presented in chapter 4, it is encouraging to note that Hepcidin 
emerged as a useful biomarker in this study. Before treatment with iron, the values 
for Hepcidin and serum iron were low. The Hepcidin levels were much lower relative 
to serum iron. The results show that Hepcidin levels are reduced in iron deplete 
states, a finding that is supported by Collins et al., (2008) and Nemeth & Ganz 
(2009). In this iron deficient state, Haemoglobin showed a better correlation to 
Hepcidin (r=0.26) than serum iron (r=0.10) as seen in Table 4.3. It is important to 
note that these correlations were weak. The weak positive associations could be 
explainable by the existence of other contributory factors in haemoglobin synthesis. 
These factors are due to the presence of complex physiological mechanisms 
available for red blood cell production. Haemoglobin synthesis directly relies on the 
presence of adequate amounts of iron.  
 
Studies by Takasawa et al., (2015) yielded slightly higher (r=0.44) correlation values 
for haemoglobin and Hepcidin which showed a moderate association between these 
two parameters. Studies by Naqvi et al., (2016) however also showed weak 
correlations in iron deficiency anaemia with serum iron and Hepcidin showing  a  
correlation  (r)  of  0.25.  In  this  current  study  as  well  as  the  one highlighted, all 
the correlations were not strong.  This highlights the significant role played  by  other  
factors  in  haemoglobin  synthesis  and  this  could  attribute  to reduced levels of 
association with the two named parameters. Inadequate iron bioavailability results 
in the formation of less haemoglobin and this has a knock-on effect on the quality of 
red cells produced which are usually less haemoglobinised and smaller in size 
(Hoffbrand a n d  Moss 2011). This morphological feature is usually termed a 
microcytic hypochromic red cell picture. Furthermore, microcytosis and 
hypochromasia directly affect red cell indices such as Mean Corpuscular 
Haemoglobin (MCV) and Mean Corpuscula Haemoglobin Concentration (MCHC). 
 
To confirm the contribution of factors other than iron and Hepcidin in the quantitative 
behaviour of haemoglobin a multiple regression analysis i nc lud ing  MCV and 
MCHC was made. Multiple regression analysis taking into account red cell 
indices such as MCV, serum iron and Hepcidin yielded an overall r value of 0.77 
further supporting the multifactorial associations  of  haemoglobin  and  other  
parameters. Multiple regression analysis is useful in predicting the value of a 
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dependant variable based on the value of at least two multiple independent 
variables. On the other hand, correlation analysis measures the strengths of 
associations between two variables.  The  simple  correlations carried out (Table 
4.3) in this study managed to place Hepcidin as a better test than serum iron on 
the basis of the strength of its association with haemoglobin levels. 
 
Generally, the studied association between haemoglobin and Hepcidin (r=0.26) 
shown in Table 4.3 is in line with observed values established elsewhere. With the 
analysis it was possible to see if the defined variables (Hepcidin and haemoglobin 
as well as serum iron and haemoglobin) move in conjunction with each other. The 
logarithmic values of Hepcidin  and  serum  iron  were  also  correlated  with  
haemoglobin.  The use  of logarithmic values corrects the skewedness that can be 
brought about by large values and therefore helps to show a clearer picture. Serum 
iron and Hepcidin values in particular have a wide range with reference normal 
Hepcidin levels stretching  from  17.80ng/mL  to  86.18ng/mL.  Logarithmic  values  
therefore become useful in clarifying the associations. Furthermore, the use of 
logarithmic  values  of  Hepcidin  resulted  in  a  statistically  significant, relatively 
moderate association with haemoglobin (r=0.37 p=0.02) in this participant group. 
The use of Hepcidin logarithmic values therefore seems to offer more diagnostic 
value as it associates better with haemoglobin levels. 
 
In addition to the effects on haemoglobin, this current study has also investigated 
the effects of various parameters on Hepcidin. Iron and haemoglobin were found 
to have relatively high positive associations of r=0.710; r=0.62 respectively with 
Hepcidin when looking at a combined group of iron deficient and non-iron deficient 
participants. This is shown in Table 4.5 and it confirms that the behaviour of Hepcidin 
is positively influenced by iron in situations where iron deficiency is not present, as 
well as where there is not enough iron available for normal physiological functions. 
The results therefore suggest that it is possible to assess the trend in iron 
bioavailability using Hepcidin levels. 
 
On the contrary, weak to moderate associations between Hepcidin and serum 
ferritin were reported by Galesloot et al., (2011). Elgari et al., (2015) also reported 
similar weak positive correlations in paediatric patients with iron deficiency anaemia. 
Naqvi et al., (2016) reported similar (r=0.25) weak association between Hepcidin 
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and serum iron. The weaker associations were reported in exclusively iron deficient 
groups. Compared to a homogenous group assessed in this study, the weaker 
correlations highlight the diminishing correlation which accompanies anaemic 
states. However, the consistent associations reported in the iron deficient study 
populations confirm that Hepcidin has a steady and constant relationship with serum 
ferritin as an indicator of iron bioavailability. Serum ferritin and serum iron 
measurements assess iron bioavailability and their relationship with Hepcidin is 
through a common hepcidin ferroportin axis (Nemeth 2010) making their 
correlations to Hepcidin comparable. In this regard, the use of serum Hepcidin may 
in no doubt add value to the diagnosis of iron deficiency anaemia. 
 
In the same analysis shown in Table 4.5 serum iron levels showed stronger 
correlations (r=0.74) than Hepcidin (r=0.62) to haemoglobin. This helps to explain 
the role played by iron bioavailability in erythropoietic activity, in particular 
haemoglobin synthesis. However, the dynamic regulation of Hepcidin by iron 
enables Hepcidin to be a highly sensitivity test in detecting IDA as shown in Table 
4.9. Dispositioning iron in this association, Hepcidin is a useful indicator of 
haemoglobin levels which could be relied upon. It is also pertinent to note that much 
higher associations were also found between haemoglobin and other full blood 
count parameters as indicated on Table 4.5. These however are part of the full blood 
count results and should be tested for in a diagnostic work up for all forms of 
anaemia. The use of Hepcidin testing would additionally be appropriate for 
differential diagnosis of iron deficiency anaemia. 
 
It is pertinent to note that the state of the severity of anaemia in most of the 
participants within the study population was not dire. The samples were obtained 
from a population of participants with mostly mild and moderate anaemia according 
to the WHO (2011) classification of anaemia. According to the WHO (2011), 
mild anaemia is defined as haemoglobin levels ranging from 110.0 to 129.0 g/L 
for men and 110.0 to119.0 g/L for women. Moderate anaemia is defined as 
haemoglobin levels between 80.0 and 100.9 g/L for both sexes and severe anaemia, 
<80.0 g/L for both sexes as well (WHO 2011). It may therefore be necessary to find 
out how both Hepcidin and serum iron correlate in severe anaemia in future studies. 
The current selection of participants is however adequate for the purpose of 




In future  studies,  larger  sample  sizes  which  include  participants with  a  wider 
variety of the degrees of anaemia would be more effective in confirming the 
usefulness of Hepcidin. This could be done as a prospective study where samples 
are tested for both Hepcidin and current parameters in the actual medical laboratory 
setting. The results could then be collated over a longer period of time giving much 
higher sample sizes which  are otherwise difficult to  attain. The current calculated 
sample size however managed to yield results which were sufficient to achieve the 
objectives of this research. 
 
5.2.2. Effects of serum iron, Hepcidin and other factors on haemoglobin: 
An analysis in IDA patients before commencing iron therapy 
 
The correlation analysis on the pre-iron treatment group shows a correlation (r) value 
of 0.10 which shows a very weak positive association between serum iron levels and 
haemoglobin values. The p value of 0.54 however indicates that this is not 
statistically significant at 5% level of significance. On the contrary, in a correlation 
analysis independent of iron, a weak positive correlation (r=0.26) was obtained 
between Hepcidin and Hb values. Although the r value for Hepcidin was weak at 
0.26 it however appears better than that for serum iron, an analyte that is already 
in routine use for the diagnosis of this ailment. Furthermore, the log Hepcidin 
correlation with haemoglobin   levels   showed   a   statistically   significant   
association (r=0.37 p=0.02). These results; highlighted in Table 4.3b above, enables 
us to underline the superior quality of Hepcidin over serum iron despite serum iron 
being one of the current routine diagnostic tests for iron deficiency anaemia. 
 
The r value for log Hepcidin was 0.37 which shows a relatively stronger relationship 
for logarithmic values of Hepcidin on haemoglobin levels. Together with the R2 
values for iron and Hepcidin shown in Table 4.3 (a & b), the results suggest that the 
contribution of Hepcidin (6.9%) to haemoglobin values is better than that for serum 
iron ( 1%). This finding m a ke s   a  reasonable  contribution  to  the  case supporting 
the use of Hepcidin in routine diagnosis of anaemia due to iron insufficiency. These 
findings support the notion that the diagnostic accuracy of Hepcidin in iron deficiency 
anaemia is better than that of serum iron, again a case supporting the  use  of  
Hepcidin  in  routine  diagnosis.  The contribution  of  the logarithmic values of 
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Hepcidin (13.4%) to haemoglobin is even higher, again supporting the notion echoed 
above that Hepcidin logarithmic values offer better diagnostic value . 
 
The relatively low correlation values of Hepcidin and iron to haemoglobin in the IDA 
participant group may possibly be attributed to the fact that the relationship is 
influenced by other factors such as erythropoietic activity. The nutrient status 
backing up the erythropoietic activity dictates the ultimate morphological features of 
red cells. Features such as microcytosis and  hypochromia  are  affected  by  
nutrient  iron  availability  and therefore has an effect on the full blood count indices 
of the red blood cells so formed. Furthermore, an increase in erythropoietic activity 
results in increased erythroid mass which consequently produces more 
erythroferrone, a hormone which suppresses Hepcidin transcription. It therefore 
becomes important to find out the role played by Hepcidin, serum iron as well as 
other factors attributable to erythropoietic activity in predicting the presence or 
absence of iron deficiency anaemia. Some of the other factors attributable to 
erythropoietic activity are the red cell indices namely MCV, MCHC, RDWcv, MCH 
and HCT. 
 
To find out the role of these multiple dependent variables, a multiple regression 
analysis was carried out. The outputs from the multiple regression analysis are 
shown in Table 4.4. the r overall (multiple R) of 77.05% shows that that the combined 
effect of parameters such as red cell count, serum iron levels, Hepcidin levels and 
red cell indices have a reasonably high effect on the variability of Haemoglobin. This 
confirms the explanation on erythropoietic activity given above.  
 
5.2.3. Iron treatment in the IDA participant group. 
 
Iron treatment resulted in an increase in serum iron, Hepcidin and haemoglobin 
levels. This was as expected and the data in Table 4.8 confirms that there was a 
positive response to iron therapy. The pre-iron and post-iron treatment differences 
are significant as indicated by the p-values obtained which are all very close to 
zero. The haemoglobin levels for all the participants rose by more than 20g/L. an 
increase of at least 20g/L is the threshold set as a benchmark to define successful 
response to iron treatment (Alleyne et al 2008). Furthermore, Hoffman et al (2013) 
suggest that a 20g/L increase in haemoglobin should be evident after three weeks. 
98 
 
The response to iron treatment experienced in this study confirmed an increase in 
iron bioavailability as indicated by increased serum iron levels. The selected 
participant group therefore managed to set the right base for studying the 
behaviour of Hepcidin in iron deficiency anaemia patients undergoing treatment. 
Non-response to iron treatment could be an indication of the presence of other 
forms of anaemia other than IDA (Hoffbrand and Moss 2011). This was however 
not the case and a positive response managed to further qualify the participant 
group as an IDA participant group.  
 
Hepcidin expression is suppressed to facilitate iron uptake (Pasricha et al., 2014) 
and this was the case as evidenced by the depressed Hepcidin values before iron 
therapy. The Hepcidin values returned to normal in the post iron treatment group 
presumably due to the iron replete state found in this group. Such an observation 
is reassuring considering the importance of the dynamics of Hepcidin in the 
prognosis of IDA patients. Hepcidin plays an important role in maintaining a 
physiological balance for iron (Ganz and Nemeth 2012). Its concentration is in turn 
regulated by the serum iron levels and this makes it a sensitive indicator of iron 
bioavailability.  
 
To further elucidate the diagnostic and prognostic value of Hepcidin, its sensitivity, 
specificity and predictive values were assessed by carrying out receiver operating 
curve (ROC) analysis. This was performed by looking at the specificity and 
sensitivity of Hepcidin in the iron deficiency anaemia group before treatment and in 
the same group after treatment. Hepcidin levels below the lower limit of normal 
were regarded as abnormal and indicative of iron deficiency. Hepcidin levels 
within the reference normal range were regarded as normal and were expected in 
non-iron deficient states such as those after iron treatment. The ranges used were 
those determined for the Namibian blood donor population in the previous chapter. 
 
The outputs form the ROC analysis such as sensitivity and specificity results were 
presented in Table 4.9. The results showed a very high specificity and sensitivity of 
100% (CI 91.19; 100.00) and 85% (CI 70.16; 94.29) respectively when using 
absolute Hepcidin levels. The positive predictive value (100% CI 89.72; 100.00) and 
negative predictive value (86.96% CI 73.74; 95.06) for Hepcidin are also high. 
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It must be noted however that these are dependent on the prevalence of the disease 
in a particular population. 
 
In this calculation, the predictive values assume a prevalence rate of 50%. This is 
an unpretentious indication of the prevalence of iron deficiency anaemia among 
anaemic patients in Namibia. The average global incidence of iron deficiency 
anaemia among anaemic patients is 50% (Stoltzfus 2003). Prevalence data for 
Namibia (WHO 2001; WHO 2011; WHO 2015) estimate the prevalence to be 40-
50%. In fact, iron deficiency is so common in anaemic patients that some authors 
(UNICEF/Namibia 2006 page 18) refer to all forms of anaemia as iron deficiency 
anaemia. This may however be misleading as other forms of anaemia are also found 
in the Namibian population. 
 
The discriminative ability of Hepcidin has been confirmed by the measures of 
diagnostic accuracy indicated in Table 4.9 above. The findings highlight the utility of 
Hepcidin as a diagnostic test for iron deficiency anaemia. Furthermore, the use of 
logarithmic values of Hepcidin tends to give better results in correlation analysis as 
indicated in Table 4.10. It may be an indication that although Hepcidin is proving to 
be a better marker, its logarithmic values may have a superior utility in diagnosing 
IDA. 
 
5.2.3.1. Observed trends i n  the prognosis of Iron Deficiency Anaemia  
 
Treatment of IDA by replenishing iron stores corrects the condition and this can be 
monitored using biochemical markers such as Hepcidin and serum iron levels. An 
increase in serum iron and Hepcidin levels is regarded as an indication of treatment 
success when monitoring the prognosis of IDA. However, increasing erythropoietic 
activity suppresses Hepcidin expression (Ashby et al., 2010) while increasing iron 
levels inhibit the suppression of Hepcidin expression (Ganz et al., 2008). There is  
an initial increase in Hepcidin levels whenever serum iron increases. This makes 
Hepcidin a sensitive marker of iron bioavailability. In this study Hepcidin levels 
increased after iron therapy. Results from this study were consistent with Ganz et 
al’s (2008) notion, our mean Hepcidin levels rose from 9.848ng/mL to 79.851ng/mL 
after iron treatment. The mean Hepcidin value increased nine times after iron 




The  magnitude  of  increase  in  Hepcidin  levels  seem  to  point  out  a  more 
pronounced response to iron levels. With Hepcidin having an immediate effect on 
iron levels (Rivera et al., 2005) it is possible that it can be used as a sensitive 
indicator of iron bioavailability. The constant associations of Hepcidin to 
haemoglobin pre- a n d  post- iron therapy, albeit low, seems to also support the 
notion that Hepcidin is sensitive to the dynamics of iron utilisation in haemoglobin 
formation. 
 
Absence of microcytosis does not exclude IDA because this morphological feature 
will appear later (Hoffbrand and Moss 2011). On the contrary presence of 
microcytosis is not always indicative of IDA because some forms of anaemia such 
as those due to haemoglobinopathies can also present with a microcytic blood 
picture. In such cases red cell indices, in particular MCV have very limited prognostic 
value. Hepcidin levels however tend to increase regardless of the red cell indices but 
in response to levels of iron bioavailability. This feature makes Hepcidin a better 
marker for iron bioavailability.  
 
Table  4.12  show the  correlations  between  Hepcidin,  serum  iron,  Δ  Hepcidin, Δ 
serum iron and haemoglobin before and after iron treatment. Serum levels of 
Hepcidin before iron treatment show a moderate correlation with haemoglobin in both 
pre (r= 0.26 p= 0.546) and post (r= 0.24 p= 0.546) treatment groups. The pre-iron 
treatment Hepcidin associations did not reach statistical significance as indicated by 
the p values in Table 4.12. The serum iron levels before treatment with iron  however  
had  lower  correlation  values  with  pre-treatment  haemoglobin (r=0.10 p=0.838) 
and post-treatment haemoglobin (r=0.05 p=0.383). Serum Hepcidin levels before 
treatment however showed a moderate positive association (r=0.46 p=0.546) with 
pre-treatment serum iron levels. Similarly, the Δ serum iron showed a moderate 
positive association (r=0.25) with Δ Hepcidin confirming the consistent association of 
baseline Hepcidin with serum iron. 
 
Another finding worth noting was the moderate negative correlation (r= -0.36) 
between baseline Hepcidin and Δ serum iron levels. Also, worth noting is the fact that 
other factors such as erythropoietic activity have an effect on the change in 




In this study there is a stronger association of Hepcidin with serum iron (r= 0.46) in 
iron deficiency anaemia before treatment compared to iron replete states after 
treatment as shown in Table 4.11. The Hepcidin serum iron correlation post iron 
treatment was lower (r=0.22) and it appears the correlation coefficients for Hepcidin 
were halved after treatment. The stronger correlations in iron deplete states has also 
been pointed out by Elgari et al., (2015). Bregman et al., (2013) also concurs with 
this finding that Hepcidin correlations with iron are stronger in iron deficiency and 
attributes this to increased erythropoietic activity amongst other factors. The 
relatively stronger correlation values in the pre-treatment IDA participant group could 
also be attributed to the dynamics of iron utilisation in iron deplete states where 
erythropoietic activity is either stable or slowing down. 
 
Another interesting finding in Table 4.11 is the correlation values for pre-iron 
treatment Hepcidin levels with haemoglobin values. The pre-iron treatment Hepcidin 
levels and pre-iron treatment haemoglobin levels had a correlation value (r) of 0.26. 
The same pre-iron treatment Hepcidin levels and post treatment haemoglobin levels 
had an r value of 0.24. The association of pre-iron treatment Hepcidin seems to be 
constant with both pre-treatment and post-treatment haemoglobin levels. Although 
the associations are weak it is important to note that these remain constant 
regardless of the iron status. 
 
5.3 Hepcidin testing in Iron Deficiency Anaemia (IDA). 
 
Results obtained in chapter 4 indicate that the quantitative behaviour of Hepcidin is 
consistent with expected findings in different iron states. In IDA, Hepcidin is reduced 
and it returns to normal in iron replete or non-IDA states. This confirms that this 
biomarker can be used as a diagnostic tool in IDA. ROC analysis showed that 
Hepcidin is both a sensitive and specific test in IDA. It is also encouraging to note 
that the magnitude of change in Hepcidin is amplified compared to haemoglobin and 
other full blood count parameters. Small changes in haemoglobin can therefore be 
detected and are more pronounced when Hepcidin values are used to interpret these 
changes on patients undergoing treatment for IDA. In all these findings, Hepcidin 












The discovery of Hepcidin has presented new opportunities in the diagnosis and 
treatment of disorders associated with iron regulation such as iron deficiency 
anaemia. Since its discovery, a lot of work has gone into understanding the 
characteristics of Hepcidin as well as its behaviour. Recently Gonzo et al., (2017) 
established reference n o rm a l  ranges for Hepcidin in the Namibian blood donor 
population. This work was the first of its kind in Namibia, a country in the southern 
part of Africa. However, not much has been done in trying to introduce it into the 
mainstream diagnostic arena for iron deficiency anaemia. The usefulness of 
Hepcidin in patients with iron deficiency anaemia has more hope and this study 
has demonstrated that it is worth considering Hepcidin testing for both the diagnosis 
and prognosis of iron deficiency anaemia. 
 
This study, to my knowledge was the first to characterise serum Hepcidin 
concentrations in Namibia more so in the Namibian blood donor population. The 
study firstly established reference normal ranges for the adult populace in Namibia 
using the Namibia blood donor population (Gonzo et al., 2017). This work has been 
published in the International Journal of Blood Transfusion and Immunohematology 
(IJBTI). The established reference normal ranges are comparable to those 
established elsewhere (Galesloot et al., 2011; Sdogou et al., 2015) affirming a 
reasonable level of external validity. 
 
Following on from establishing the reference normal ranges, characterisation of 
Hepcidin in iron deficiency anaemia (IDA) was carried out. From other studies, 
Hepcidin levels are depressed in iron deplete states (Collins et al., 2008; Nemeth 
& Ganz 2009) and this is consistent with findings from this study. The Hepcidin 
levels were suppressed in the pre-iron treatment IDA study group. Serum iron and 
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haemoglobin levels were also reduced indicating the presence of an iron deficient 
state. In this state,  haemoglobin levels  demonstrated a  moderate  positive  
correlation  (r= 0.26)  with  Hepcidin. 
 
Although   the   association   was   moderate, it   was   stronger   than   between 
haemoglobin and serum iron which was r=0.10. The analysis therefore confirmed 
the presence of a relationship between Hepcidin and current markers of iron 
bioavailability.  
 
Hepcidin values in iron deficiency and iron replete states were found to be 
significantly different in the population under study confirming its diagnostic ability to 
discriminate between iron deficiency and healthy states. In the post iron treatment 
IDA group both serum iron and haemoglobin levels were increased confirming a 
correction of both iron bioavailability and anaemia. It can be inferred that the 
correction of anaemia was a result of the correction of iron levels. This observation 
confirms the presence of iron deficiency anaemia in the initial IDA study population 
as well the effectiveness of the iron treatment intervention in this study population. 
 
The physiological mechanisms involved in Hepcidin regulation are mainly dependent 
on iron bioavailability (Knutson 2010). This makes Hepcidin levels a more specific 
index for iron status. Reduced Hepcidin levels are associated with reduced  iron  
bioavailability  and  increased  erythropoietic  activity  (Ganz  et  al.,2008). Inversely, 
a correction of depressed Hepcidin expression indicates improved iron bioavailability 
as well as decelerated erythropoietic activity and this would occur once IDA is 
corrected. In this study, an increase in Hepcidin levels was noted in the post iron 
treatment study population as indicated by an increased mean Hepcidin level in 
Table 4.8.  In this same study, Hepcidin has demonstrated that its association 
with haemoglobin is comparable to that of the currently used measures of iron 
bioavailability. This makes it a potential candidate for the diagnosis and 
prognosis of iron deficiency anaemia.  
 
Increments in haemoglobin and serum iron, (as seen in Figure 4.5 and 4.6) shows 
that serum iron increased by a higher magnitude compared to haemoglobin levels. 
On average, the percentage increase in serum iron level was 353.2% compared to 
14.6% for haemoglobin levels. These are significant increases, furthermore the 
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magnitude of iron increments is worrying if the risk of iron overload is put into 
perspective. In their review, Alleyne et al., (2008) highlighted that haemoglobin 
levels are expected to increase by about 20g/L within 4 weeks for patients on iron 
supplementation. To avert the risk of iron overload in patients undertaking iron 
therapy it  may  be  pertinent  to  rely  on  the  dynamics  of  Hepcidin.  Hepcidin 
increments post iron treatments are more pronounced than serum iron levels for the 
same amount of iron administered. Moreover, Hepcidin correlations with 
haemoglobin were found to be better compared to iron-haemoglobin associations. 
We may therefore be able to ascertain adequacy of iron by using Hepcidin testing.  
 
The use  of  logarithmic  values  of  Hepcidin  may  even  be  more appealing because 
they give better correlations with haemoglobin levels. The improved correlations 
found with logarithmic values of Hepcidin are due to the fact that data which is 
presented as logarithms is less skewed. In our case the correction of the degree of 
skewedness resulted in a more linear relationship and thus higher correlation values. 
This highlights the superior utility of log Hepcidin compared to absolute Hepcidin 
values. 
 
Hepcidin levels may also be useful in the differential diagnosis of pure IDA and 
IDA in anaemia of chronic disease (ACD). In ACD conditions such as irritable 
bowel syndrome and cancer related anaemia, IDA can arise as a result of 
gastrointestinal bleeding and the use of anti-cancer treatment regiments (Shu et al., 
2015; Bergamaschi et al., 2013). In such cases Hepcidin is upregulated in pure ACD 
but suppressed in ACD with concomitant iron deficiency (Theurl et al., 2009). With 
such dynamics in Hepcidin levels, it may be possible to use it to clarify the aetiology 
of IDA, this has however not been pursued in this study. 
 
In summary, Hepcidin concentrations are related to levels of iron bioavailability and 
the association exists in both iron deplete as well as iron replete states. Hepcidin 
levels progressively rise as haemoglobin levels increase indicating a transition 
from iron deplete to iron replete state. The rise in Hepcidin levels is however more 
pronounced than in haemoglobin. This is a useful attribute for monitoring response 








The use of Hepcidin in a routine diagnostic setting has great potential. In this study 
it was possible to establish reference normal ranges as well as demonstrate the 
quantitative differences of Hepcidin levels in diseased and non-diseased states. The 
expected Hepcidin levels in both iron replete and iron deficient states were 
consistent with what was found in this study further confirming its ability to distinguish 
between IDA and non-IDA states. 
 
This study determined the sensitivity and specificity of Hepcidin at the lower limit of 
normal as defined by the reference normal range established by the same study. 
These findings indicated t h a t  H e p c i d i n  h a s  v e r y  high sensitivity (100%) and 
specificity (85%) for IDA. Such findings support the notion for introducing Hepcidin 
into the routine diagnostic arena. Furthermore, the predictive values, both positive 
and negative, were found to be high. This highlights the fact that Hepcidin testing is 
able to confirm the presence of IDA in diseased patients as well as ruling out its 
presence in non-IDA patients. 
 
A potential limitation of Hepcidin as a routine test for the diagnosis of iron deficiency 
anaemia is the inherent diurnal variation (Nemeth 2010; Kroot et al.,2009). This 
constraint is common with most hormones (van Kerkhorf et al., 2015) and proper 
sampling will help to overcome this impediment. Furthermore, once all pre-analytical 
variables for Hepcidin are established, sample preparation can be tailored to 
minimise them. This exercise is a common practice in medical diagnostics and will 




Based on the findings in this study, work towards implementing Hepcidin testing in 
routine diagnosis for iron deficiency anaemia should continue. Before the full 
implementation of Hepcidin testing in Namibia the following considerations should 





6.3.1. Hepcidin testing  
 
Implementation of Hepcidin testing primarily for the diagnosis and prognosis of iron 
deficiency anaemia along with current testing methods is recommended. The 
rationale for the implementation is to enable the validation of this test in the new 
environment and to enable collection of more data on the behaviour of Hepcidin 
in iron deficiency anaemia in different clinical settings.  In  implementing routine 
Hepcidin testing laboratories should consider the use of reference preparations 
of  Hepcidin to quality control their runs. The reference preparations would also 
enable inter- laboratory comparison of assay runs, a motion which has also been 
echoed by Pasricha et al., (2011) 
 
6.3.2. Reference normal range  
 
Establish reference normal ranges which are stratified by age and gender to enable 
interpretation of results in the respective demographic scenarios. This should be 
prioritised. To fulfil this, a more extensive sampling strategy which takes into 
consideration the populat ions f rom  different  geographical  areas  within  
Namibia  should  be employed. Sampling should transcend beyond the 
boundaries of the Namibian blood donor community. 
 
In conclusion the use of Hepcidin testing should be highlighted and encouraged in 
the Namibian treatment guidelines. The Namibian treatment guidelines (MoHSS 
2011) is the medium in which the country communicates guidelines on the diagnosis 
and management of disease including iron deficiency anaemia. 
 
6.3.3. Further testing 
 
Further testing should be carried out which investigates the correlations between  
reticulocyte  parameters  and  Hepcidin  in  the  Namibian population. The study 
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